Document:

Exhibit
10.4

 

 

 

 

 

 

 

 

LICENSE,
DEVELOPMENT

 

AND
COMMERCIALIZATION AGREEMENT

 

 BETWEEN

 

AMPIO
PHARMACEUTICALS, INC.

 

AND

 

DAEWOONG
PHARMACEUTICALS CO., LTD

 

 

 

 

 

 

 

 

 

     

     

    

 

LICENSE,
DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

 

	1	DEFINITIONS	1
	 	 	 
	2	LICENSES	7
	 	 	 
	3	DISCLOSURE OF KNOW-HOW	9
	 	 	 
	4	MILESTONE PAYMENTS	10
	 	 	 
	5	MANAGEMENT; JOINT STEERING COMMITTEE	11
	 	 	 
	6	DEVELOPMENT	12
	 	 	 
	7	REGULATORY MATTERS	14
	 	 	 
	8	COMMERCIALIZATION	18
	 	 	 
	9	MANUFACTURE AND SUPPLY; PAYMENT FOR PRODUCTS	18
	 	 	 
	10	REPRESENTATIONS, WARRANTIES AND COVENANTS; DISCLAIMER	21
	 	 	 
	11	INTELLECTUAL PROPERTY	24
	 	 	 
	12	CONFIDENTIALITY/PUBLICATIONS	30
	 	 	 
	13	TERM AND TERMINATION	32
	 	 	 
	14	EFFECTS OF TERMINATION OR EXPIRATION	33
	 	 	 
	15	ANNOUNCEMENT	34
	 	 	 
	16	GOVERNING LAW	34
	 	 	 
	17	DISPUTE RESOLUTION	35
	 	 	 
	18	NOTICES	36
	 	 	 
	19	FORCE MAJEURE	36
	 	 	 
	20	INDEMNIFICATION AND INSURANCE	37
	 	 	 
	21	NON-ASSIGNABILITY	39
	 	 	 
	22	LANGUAGE	40
	 	 	 
	23	ENTIRE AGREEMENT	40
	 	 	 
	24	SEPARABILITY	40
	 	 	 
	25	INDEPENDENT CONTRACTORS; NO PARTNERSHIP	40
	 	 	 
	26	AMENDMENT AND WAIVER	41
	 	 	 
	27	COUNTERPARTS	41

   

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page i	 

     

    

 

THIS LICENSE, DEVELOPMENT
AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is made and entered into on August 23, 2011 (the “Effective
Date”) by and between Ampio Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 5445
DTC Parkway, Suite 925, Greenwood Village, Colorado 80111 (“Ampio”), and Daewoong Pharmaceuticals Co., Ltd, having
its principal place of business at 163-3 Samsungdong, Kangnam-gu, Seoul, Republic of Korea (“Daewoong”). Each of Ampio
and Daewoong is sometimes referred to herein as a “Party” and collectively, as the “Parties.”

 

WHEREAS, Ampio has developed certain intellectual
property relating to the use of Tramadol for the treatment of premature ejaculation;

 

WHEREAS, Daewoong has substantial
expertise in the research, development, distribution, sales and marketing of pharmaceutical products in the Republic of Korea;
and

 

WHEREAS, Ampio desires
to grant to Daewoong, and Daewoong desires to obtain from Ampio, the right to develop, market and sell products containing Tramadol
for certain indications in the Republic of Korea, all on the terms and conditions set forth herein.

 

NOW, THEREFORE, in consideration
of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties hereto agree
as follows:

 

1 Definitions

 

1.1 “Affiliate” means any corporation,
firm, partnership, limited liability company or other entity that controls, is controlled by or is under common control with a
Party to this Agreement. For purposes of this definition, any entity will be regarded as in “control” of another entity
if (a) it directly or indirectly owns more than fifty percent (50%) of the voting stock of the other entity or such lesser maximum
percentage permitted in those jurisdictions where majority ownership by foreign entities is prohibited, (b) it owns or has a right
to own more than fifty percent (50%) of the net assets of an entity without voting securities, or (c) it possesses, directly or
indirectly, the power to direct or cause the direction of the management and policies of the entity, whether through contract or
otherwise.

 

1.2 “Ampio” means
Ampio Pharmaceuticals, Inc.

 

1.3 “Ampio Know-How” means
all Information that is Controlled by Ampio or its Affiliates as of the Effective Date or during the Term and is necessary or
useful for the Development, Manufacture or Commercialization of the Product in the Field in accordance with the terms of this
Agreement. For clarity, Ampio Know-How excludes Information claimed in any Ampio Patent. For avoidance of doubt, Ampio
Know-How shall exclude the Information of any Third Party that becomes an Acquiror of Ampio, except for any Information
included within the definition of “Ampio Know-How” that is developed by such Acquiror after the closing of such
acquisition in the course of conducting activities on behalf of Ampio under this Agreement.

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 1	 

     

    

 

1.4 “Ampio Licensee” means licensees
of Tramadol and/or Products outside the Territory during the Term of this Agreement, under any Ampio Patents (both inside and outside
the Territory), Ampio Know-How or Ampio Regulatory Documentation.

 

1.5 “Ampio Patents”
means any Patent that (a) is Controlled by Ampio or its Affiliates as of the Effective Date or at any time during the Term, and

 

(b) claims the composition of matter, use or Manufacture
of a Product in the Field. A list of Ampio Patents in existence as of the Effective Date is attached hereto as Exhibit 1.5, and
Ampio shall update such list from time to time to include additional Ampio Patents, including patents issuing from any listed application
or claiming priority thereto or otherwise continuing therefrom. For the avoidance of doubt, Ampio Patents shall include Product
Patents (as defined in Section 11.1), and shall exclude the Daewoong Patents and the Patents of any Third Party that becomes an
Acquiror of Ampio, except for (i) any Patents claiming inventions that are included within the definition of an “Ampio Patent”
that are developed by such Acquiror in the course of conducting activities on behalf of Ampio under this Agreement, or (ii) any
Patents Controlled by such Acquiror at the closing of the acquisition of Ampio that claim the composition, use or manufacture of
the Product as in existence as of the Effective Date.

 

1.6 “Ampio Technology”
means the Ampio Patents and Ampio Know-How.

 

1.7 “CMC” means
chemistry, manufacturing and controls as specified by the FDA.

 

1.8 “Combination Product”
means a Product that includes Tramadol and a PDE5 inhibitor.

 

1.9 “Commercially Reasonable Efforts”
means those efforts consistent with the exercise of prudent scientific and business judgment in an active and ongoing program as
applied by a Party to the development and commercialization of its own pharmaceutical products at a similar stage of development
and with similar market potential. Commercially Reasonable Efforts requires that a Party, at a minimum, assigns responsibility
for such obligations to qualified employees, sets annual goals and objectives for carrying out such obligations, and allocates
resources designed to meet such goals and objectives.

 

1.10 “Commercialization” with a correlative
meaning for “Commercialize” and “Commercializing”, means all activities undertaken before and after obtaining
Regulatory Approvals relating specifically to the pre-launch, launch, promotion, detailing, medical education and medical liaison
activities, marketing, pricing, reimbursement, sale, and distribution of the Products, including: (a) strategic marketing, sales
force detailing, advertising, medical education and liaison, and market and Product support; (b) any postmarketing clinical studies
for use in generating data to be submitted to Regulatory Authorities (and all associated reporting requirements); and (c) all customer
support, Product distribution, invoicing and sales activities.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 2	 

     

    

 

1.11 “Confidential Information” means,
with respect to a Party, all reports and other Information of such Party that is disclosed to the other Party under this Agreement,
whether in oral, written, graphic, electronic or other form. All Information disclosed by either Party pursuant to the Mutual Confidentiality
Agreement between the Parties dated December 8, 2010 (the “Mutual CDA”), shall be deemed to be such Party’s Confidential
Information disclosed hereunder.

 

1.12 “Control” means, with respect
to any material, Information, or intellectual property right, that a Party owns or has a license to such material, Information,
or intellectual property right and, in each case, has the ability to grant to the other Party access, a license, or a sublicense
(as applicable) to the foregoing on the terms and conditions set forth in this Agreement without violating the terms of any then-existing
agreement or other arrangement with any Third Party.

 

1.13 “Develop”
or “Development” means all activities relating to preparing and conducting preclinical testing, toxicology testing,
human clinical studies, and regulatory activities (e.g., regulatory applications) with respect to the Product, together with the
manufacturing of the Product for the purpose of conducting the foregoing activities.

 

1.14 “Development Costs” means the
internal costs and out-of-pocket costs incurred as an expense by or on behalf of a Party or its Affiliates in carrying out the
Development of the Product in accordance with the approved Development Plan, including, without limitation, (i) the costs of clinical
trials (including costs of procuring the Product(s), placebos and comparator drugs used in such clinical trials), (ii) filing fees
and other costs associated with any Regulatory Filings; (iii) costs related to manufacturing development; and (iv) all other costs
that are directly attributable and reasonably allocable to the Development activities for the Products. For purposes of this definition:
(a) out-of-pocket costs mean the actual expense incurred with respect to a Third Party for specific Development activities relating
to the Products; and (b) internal costs means the applicable FTE rate multiplied by the number of FTE hours expended in carrying
out the Development activities in accordance with the Development Plan. For clarity, the costs associated with attending or participating
in meetings of the JSC are expressly excluded from this definition.

 

1.15 “Dollar” means
a U.S. dollar, and “$” shall be interpreted accordingly.

 

1.16 “Daewoong”
means Daewoong Pharmaceuticals Co., Ltd.

 

1.17 “Daewoong Know-How” means
all Information that (a) is Controlled by Daewoong or its Affiliates as of the Effective Date and applied or used in connection
with the Development, Manufacture or Commercialization by Daewoong of the Product, or (b) arises from Daewoong’s activities
under this Agreement, but excluding any and all Product Inventions (as defined in Section 11.1). For clarity, Daewoong Know-How
excludes Information claimed in any Daewoong Patent. For the avoidance of doubt, Daewoong Know-How shall exclude the Information
of any Third Party that becomes an Acquiror of Daewoong, except for any Information included within the definition of “Daewoong
Know-How” that is developed by such Acquiror after the closing of such acquisition in the course of conducting activities
on behalf of Daewoong under this Agreement. 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 3	 

     

    

 

1.18 “Daewoong Patent” means any
Patent that (a) is Controlled by Daewoong or its Affiliates as of the Effective Date and applied or used in connection with the
Development, Manufacture or Commercialization by Daewoong of the Product hereunder, or (b) claims any inventions made by Daewoong,
other than the Product Inventions (as defined in Section 11.1), in the course of conducting its activities under this Agreement.
A list of the Daewoong Patents in existence as of the Effective Date, if any, is as attached hereto as Exhibit 1.18, and Daewoong
shall update such list from time to time to include additional Daewoong Patents, including patents issuing from any listed application
or claiming priority thereto or otherwise continuing therefrom. For the avoidance of doubt, Daewoong Patents shall exclude the
Patents of any Third Party that becomes an Acquiror of Daewoong, except for (i) any Patents claiming inventions that are included
within the definition of a “Daewoong Patent” that are developed by such Acquiror in the course of conducting activities
on behalf of Daewoong under this Agreement, or (ii) any Patents Controlled by such Acquiror at the closing of the acquisition of
Daewoong that claim the composition, use or manufacture of the Product as in existence as of the Effective Date.

 

1.19 “Daewoong Technology”
means the Daewoong Patents and Daewoong Know-How.

 

1.20 “FDA” means
the United States Food and Drug Administration and any successors thereof.

 

1.21 “Field” means
the treatment of premature ejaculation and/or erectile dysfunction.

 

1.22 “Finish” means
to label and package vials or other containers of a Product suitable for distribution to final users.

 

1.23 “First Commercial Sale” means
the first sale to a Third Party of a Product in a given regulatory jurisdiction after Regulatory Approval has been obtained in
such jurisdiction.

 

1.24 “Governmental Authority” means
any multi-national, federal, state, local, municipal, provincial or other government authority of any nature (including any governmental
division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal).

 

1.25 “Information” means any
data, results, technology, business information and information of any type whatsoever, in any tangible or intangible form, including,
without limitation, know-how, trade secrets, practices, techniques, methods, processes, inventions, developments, specifications,
formulations, formulae, materials or compositions of matter of any type or kind (patentable or otherwise), software, algorithms,
marketing reports, expertise, technology, test data (including pharmacological, biological, chemical, biochemical, toxicological,
preclinical and clinical test data), analytical and quality control data, stability data, other study data and procedures. 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 4	 

     

    

 

1.26 “Laws” means all laws, statutes,
rules, regulations, ordinances and other pronouncements having the effect of law of any federal, national, multinational, state,
provincial, county, city or other political subdivision, domestic or foreign, including any regulatory agency policy or informal
regulatory agency guidance.

 

1.27 “Manufacture” with a correlative
meaning for “Manufacturing,” means all activities related to the manufacturing of a pharmaceutical product, or any
ingredient thereof, including manufacturing Product in finished form for Development, manufacturing finished Product for Commercialization,
packaging, in-process and finished Product testing, release of Product or any component or ingredient thereof, quality assurance
activities related to manufacturing and release of Product, ongoing stability tests and regulatory activities related to any of
the foregoing.

 

1.28 “Net Sales” means the gross sales
price for the Product invoiced by Daewoong or any of its Affiliates or Sublicensees to Third Party customers for sales or other
transfers or dispositions for consideration of a Product, less (i) documented discounts (including customary trade, quantity, cash
and patient discount programs discounts), retroactive price reductions, charge-back payments and rebates granted to managed health
care organizations or to federal, state and local governments, their agencies, and purchasers and reimbursers or to trade customers;
(ii) credits for returns, such as unrecoverable damaged goods or rejections and including Product returned in connection with recalls
or withdrawals; (iii) transportation charges including insurance; and (iv) any value added taxes or governmental charges, including
custom duties, levied on the sale of the Product. Net Sales shall not include any payments among Daewoong, its Affiliates and Sublicensees.

 

1.29 “Patent” means (a) pending patent
applications (and patents issuing therefrom), issued patents, utility models and designs; and (b) reissues, substitutions, confirmations,
registrations, validations, re-examinations, additions, continuations, continued prosecution applications, continuations- in-part,
or divisions of or to any patents, patent applications, utility models or designs, in each case being enforceable within the applicable
territory.

 

1.30 “Product” means any formulation
that includes Tramadol that is suitable for use in the Field. Product includes, without limitation, Combination Products.

 

1.31 “Regulatory Approval” means,
with respect to a Product in any country or jurisdiction, all approvals (including, where required, pricing and reimbursement
approvals), registrations, licenses or authorizations from the relevant Regulatory Authority in a country or jurisdiction that
is specific to Product and necessary to market and sell such Product in such country or jurisdiction. 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 5	 

     

    

 

1.32 “Regulatory Authority”
means, in a particular country or regulatory jurisdiction, any applicable Governmental Authority involved in granting
Regulatory Approval and/or, to the extent required in such country or regulatory jurisdiction, pricing or reimbursement
approval of a Product in such country or regulatory jurisdiction.

 

1.33 “Regulatory Documentation” means
all Regulatory Filings, registrations, filings, applications, licenses, authorizations and approvals (including Regulatory Approvals),
all correspondence submitted to or received from Regulatory Authorities (including minutes and official contact reports relating
to any communications with any Regulatory Authorities), and all clinical studies, data and supporting documents contained therein,
in each case relating to Tramadol or the Products, and all data contained in any of the foregoing (including advertising and promotional
and marketing documents, adverse event files, PSURs, medical event reports, compliant files and the like).

 

1.34 “Regulatory Filings” means, with
respect to the Products, any submission to a Regulatory Authority of any appropriate regulatory application specific to Products,
and shall include, without limitation, any submission to a regulatory advisory board and any supplement or amendment thereto.

 

1.35 “Retained Territory”
means all countries and territories in the world other than the Territory.

 

1.36 “Territory”
means the Republic of Korea.

 

1.37 “Third Party”
means any party other than a Party to this Agreement and such Party’s Affiliates.

 

1.38 “Tramadol” means 2-[(dimethylamino)methyl]-
1-(3-methoxyphenyl)-cyclohexanol and all pharmaceutically-acceptable forms (e.g., solvates, polymorphs and salts) thereof.

 

1.39 “Tramadol Only Product”
means a Product that includes Tramadol only.

 

1.40 “Transfer Price”
means US$0.97 per tablet, subject to annual adjustment as set forth in the Supply Agreement.

 

1.41 “Valid Claim” means any claim
contained in any Ampio Patent in the Territory which has not been revoked or held unenforceable, unpatentable or invalid by a decision
of a court or other governmental agency or competent jurisdiction, unappealable or unappealed within the time allowed for appeal,
and which has not been admitted to be invalid or unenforceable through abandonment, reissue, disclaimer or otherwise.

 

1.42 “Zertane” means Ampio’s
trademark and/or trade dress for Tramadol. 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 6	 

     

    

 

2 Licenses

 

2.1 License to Daewoong.

 

(a) Subject to the terms and conditions of this
Agreement, Ampio hereby grants Daewoong an exclusive (even as to Ampio except as provided in this Section 2.1 below), royalty-bearing
license, with the right to sublicense directly or through multiple tiers as provided in Section 2.3, under the Ampio Technology,
to research, Develop, Finish, use, have used, sell, have sold, offer for sale, have offered for sale, distribute, have distributed,
import, have imported, and otherwise Commercialize the Products in the Field in the Territory. For clarity, the foregoing licenses
exclude the right to Manufacture or have Manufactured the Product, except for the right to Finish the Product.

 

(b) Notwithstanding the rights granted to Daewoong
in Section 2.1 and without limiting the generality of Section 2.4, Ampio retains the following: (i) the right to conduct or have
conducted clinical trials and other studies in the Territory for the generation of data in support of any regulatory submissions
to any Regulatory Authority in the Retained Territory; and (ii) the right to Manufacture or have Manufactured Product anywhere
in the Territory, in each case together with the right to import and export the Product in such territories for such purposes.

 

2.2 License to Ampio.
Subject to the terms and conditions of this Agreement, Daewoong hereby grants to Ampio (a) a non-exclusive, royalty-free license
(with the right to sublicense as provided below) in the Field under the Daewoong Technology to Develop, use, make, and have made
the Products in the Territory pursuant to the terms of this Agreement and the Supply Agreement, and (b) a non-exclusive, royalty-free,
perpetual, irrevocable license, with the right to grant sublicenses through multiple tiers, under the Daewoong Technology to research,
develop, use, have used, sell, have sold, offer for sale, have offered for sale, distribute, have distributed, import, have imported,
export, have exported and otherwise commercialize the Products in the Retained Territory.

 

2.3 Sublicenses.

 

(a) Daewoong may grant
sublicenses to one or more Third Parties (any such Third Parties, together with all their direct and indirect Sublicensees, collectively,
”Sublicensees”) of the licenses granted to Daewoong hereunder, subject to Ampio’s prior written consent with
respect to the identity of the potential Sublicensee, such consent shall not be unreasonably withheld. Daewoong shall remain responsible
for the performance of its obligations set forth herein by each of its Sublicensees. 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 7	 

     

    

 

(b) Daewoong
shall, within thirty (30) days after granting any sublicense under Section 2.1(a) above, notify Ampio of the grant of such
sublicense and provide Ampio with a true and complete copy of such sublicense agreement. Each sublicense agreement shall not
conflict with the terms and conditions under this Agreement. Daewoong shall, in each agreement under which it grants a
sublicense under the license set forth in Section 2.1 (each, a “Sublicense Agreement”), include the following
terms and conditions: (i) the Sublicensee is required to carry out such tasks to ensure that Daewoong will comply with its
obligations to Ampio hereunder; (ii) the Sublicensee is required to provide the following to Daewoong if such Sublicense
Agreement terminates during the term of this Agreement: (A) the assignment and transfer of ownership and possession of all
Regulatory Filings and Regulatory Approvals held or possessed by such Sublicensee, and (B) the assignment of all intellectual
property Controlled by such Sublicensee that covers or embodies a Product or its respective use, manufacture, sale, or
importation and was created by or on behalf of such Sublicensee during the exercise of its rights or fulfillment of its
obligations pursuant to such Sublicense Agreement; and (iii) if this Agreement terminates pursuant to Section 13.2 prior to
the expiration of the Term, then Ampio may, at its sole discretion: (X) assume Daewoong’s rights and obligations under
such Sublicense Agreement; or (Y) terminate such Sublicense Agreement. Each Sublicense Agreement shall include the
Sublicensee’s obligations set forth herein.

 

2.4 Negative Covenant; No Implied License.
Each Party covenants that it will not use or practice any of the other Party’s intellectual property rights licensed to it
under this Article 2 except for the purposes expressly permitted in the applicable license grant. Except as explicitly set forth
in this Agreement, neither Party grants any license, express or implied, under its intellectual property rights to the other Party.

 

2.5 Diversion.

 

(a) Daewoong hereby covenants
and agrees that it will not, and will ensure that its Affiliates, Sublicensees and subcontractors will not, either directly or
indirectly, promote, market, distribute, import, sell or have sold Products, including via the Internet or mail order, to any
Third Party, address or Internet Protocol (“IP”) address in the Retained Territory. As to such countries in the Retained
Territory: (i) Daewoong shall refrain from establishing or maintaining any branch, warehouse or distribution facility for the
Product in such countries; (ii) Daewoong shall not engage in any advertising or promotional activities relating to the Products
directed primarily to customers or other buyers or users of the Products located in such countries; and (iii) Daewoong shall not
solicit orders from any prospective purchaser located in such countries. If Daewoong receives any order from a prospective purchaser
located in a country in the Retained Territory, Daewoong shall immediately refer that order to Ampio. Daewoong shall not accept
any such orders. Daewoong may not deliver or tender (or cause to be delivered or tendered) any Products outside of the Territory. 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 8	 

     

    

 

(b) If any of Daewoong’s Products is diverted
for use in the Retained Territory, the following shall apply: (i) if such Product were diverted by an identifiable customer, distributor,
employee, consultant or agent of Daewoong then, upon the request of Ampio, Daewoong shall not sell such category of Product to,
or allow the sale of such category of Product by, any such customer, distributor, employee, consultant or agent for the remaining
Term and shall use commercially reasonable efforts to buy back all such Product from such customer, distributor, employee, consultant
or agent within seven (7) business days of receiving such request from Ampio; or (ii) Daewoong shall use commercially reasonable
efforts to investigate the location of such diverted Product and buy it back; but, if and to the extent that, Daewoong elects not
to, or is unable to, buy back the applicable diverted Product, then Ampio may, in its sole discretion, buy back the applicable
diverted Product and Daewoong shall reimburse Ampio for all reasonable costs incurred by Ampio in connection with the buy-back
of any such diverted Product.

 

2.6 Exclusivity.
During the Term: (a) neither Daewoong nor its Affiliates will, either by itself or through the grant of licenses or sublicenses,
without Ampio’s written consent, commercialize any formulation that includes Tramadol in the Field in the Territory or in
the Retained Territory except under this Agreement; and (b) Daewoong will not, and will ensure that its Affiliates will not, either
by itself or through the grant of licenses or sublicenses: commercialize another product for the treatment of premature ejaculation
and/or erectile dysfunction in the Territory.

 

2.7 Registration of
License. Daewoong shall have the right to record or register the licenses granted hereunder, and allow its Sublicensees to
record or register the sublicenses granted under the Sublicense Agreement, at any patent office or other relevant authority in
the Territory. Ampio shall execute all documents and give all declarations regarding the licenses or sublicenses and reasonably
cooperate with Daewoong or its Sublicensees at the costs of Daewoong or its Sublicensees to the extent such documents, declarations
and/or cooperation are required for such record or registration of the licenses or sublicenses for the benefit of Daewoong or its
Sublicensees.

 

3 Disclosure of Know-How

 

3.1 Disclosure of Ampio Know-How and Ampio
Regulatory Documentation. Within sixty (60) days after the Effective Date of this Agreement, Ampio shall disclose or make available
to Daewoong copies of all of the Ampio Know-How and Ampio Regulatory Documentation, including such Ampio Know-How and Ampio Regulatory
Documentation identified on Exhibit 3.1. Thereafter during the term of this Agreement, Ampio shall disclose and make available
to Daewoong all future Ampio Know-How and Ampio Regulatory Documentation on a regular basis, provided that all material new Ampio
Know-How and Ampio Regulatory Documentation shall be provided without delay.

 

3.2 Disclosure of Daewoong Know-How and
Daewoong Regulatory Documentation. Daewoong shall disclose or make available to Ampio, during the term of this Agreement,
any and all Daewoong Know-How and Daewoong Regulatory Documentation on a regular basis, provided that all material Daewoong Know-How
and Daewoong Regulatory Documentation shall be provided without delay. 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 9	 

     

    

 

4 Milestone Payments

 

4.1 Milestone Payments. In consideration
of the rights and licenses granted to Daewoong by Ampio hereunder, Daewoong shall pay to Ampio the following milestone amounts:

 

	Event	 	Payment (U.S. Dollars)	 
	1.	Upon signing of this Agreement by both Parties	 	$	500,000	 
	2.	Within five (5) business days following the approval of Tramadol for sale in the Territory	 	$	500,000	 
	3.	Within five (5) business days following the approval of the Combination Product for sale in the Territory	 	$	700,000	 
	4.	 Within twenty (20) business days following the end of the first calendar quarter where cumulative Net Sales in the Territory
exceed US$10 million	 	$	 1 million	 
	5.	Within twenty (20) business days following the end of the first calendar quarter whether cumulative Net Sales in the Territory
exceed US$20 million	 	$	 1 million	 
	TOTAL PAYMENTS	 	$	3,700,000	 

 

For clarity, milestone events 4 and 5 may occur
during the same calendar year, in which event each of the accompanying milestone payments shall become due. In addition, the milestones
will apply to sales of Products by Daewoong, its Affiliates and Sublicensees.

 

4.2 Non-Refundable.
Any payments made by Daewoong in accordance with Section 4.1 shall, once they are paid, not be refundable nor creditable for any
reason whatsoever, unless otherwise expressly provided herein.

 

4.3 Single Payments. The payments
specified in Section 4.1 shall be made only one time upon the first occurrence of the event described in Section 4.1, regardless
of how many times such event may be achieved with regard to the Products covered by this Agreement. 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 10	 

     

    

 

5 Management; Joint Steering
Committee

 

5.1 Alliance Managers. Within
thirty (30) days following the Effective Date, each Party will appoint (and notify the other Party of the identity of) a
representative having the appropriate qualifications including a general understanding of pharmaceutical Development and
Commercialization issues to act as its alliance manager under this Agreement (“Alliance Manager”). The Alliance
Managers will serve as the primary contact points between the Parties for the purpose of providing each Party with
information on the progress of the other Party’s Development and Commercialization of the Products. The Alliance
Managers will also be primarily responsible for facilitating the flow of information and otherwise promoting communication,
coordination and collaboration between the Parties, providing single point communication for seeking consensus both
internally within each Party’s respective organization, including facilitating review of external corporate
communications, and raising cross-Party and/or cross-functional disputes in a timely manner. Each Party may replace its
Alliance Manager on written notice to the other Party.

 

5.2 Joint Steering Committee.

 

(a) Within thirty (30) days after the Effective
Date, the Parties will establish a joint steering committee (the “Joint Steering Committee” or “JSC”) to
plan, administer, evaluate and carry out all aspects of the Development, manufacture, regulatory and Commercialization activities
by Daewoong hereunder with respect to the Products.

 

(b) The JSC will consist of representatives
of Ampio and Daewoong. The representatives may be from various functional groups (e.g., clinical development, regulatory, medical
affairs, pharmacovigilance, commercial and manufacturing). Daewoong will appoint a chair of the JSC.

 

(c) The Parties shall schedule the
half-yearly JSC meetings and agree to such schedule at least quarterly in advance. Either Party may call additional ad hoc
meetings of the JSC as the needs arise with reasonable advance notice to the other Party, and such ad hoc meetings shall be
conducted at times that are mutually agreed upon by the Parties. All meetings and other communications of the JSC shall be
conducted in English. No later than five (5) business days prior to any regularly scheduled meeting of the JSC, the
chairperson of the JSC shall prepare and circulate an agenda for such meeting and, as soon as practicable, all materials,
documents and information for the meeting for distribution to both Parties; provided, however, that either Party may propose
additional topics to be included on such agenda, either prior to or in the course of such meeting. The JSC may meet in
person, by videoconference or by teleconference. The chairperson of the JSC will be responsible for preparing reasonably
detailed written minutes of all JSC meetings that reflect, without limitation, material decisions made at such meetings. The
JSC chairperson shall send draft meeting minutes to the Daewoong members and the Ampio members of the JSC for review and
approval within ten (10) business days after each JSC meeting. Such minutes will be deemed approved unless one or more
members of the JSC objects to the accuracy of such minutes within ten (10) business days of receipt. Further, upon
Daewoong’s request, Ampio will use commercially reasonable efforts to coordinate any meeting among Ampio, Daewoong and
any other Ampio Licensees for the exchange of information helpful for the Development of the Products. In addition to
the regularly scheduled meetings, Daewoong shall call additional ad hoc meetings of the JSC prior to making any major
decisions in the Development of the Products in the Territory. The Parties shall also maintain regular, frequent and informal
communications for Ampio to obtain updates from Daewoong and for the Parties to discuss the progress of the Development of
the Products in the Territory.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 11	 

     

    

 

(d) The JSC shall strive to seek consensus in
its actions and decision making process. In the event of a disagreement between the Ampio members and Daewoong members of the JSC,
either Party may refer the matter to one senior executive of each Party (i.e., the Chief Executive Officer or Managing Director
of such Party or an executive of such Party who reports directly to the Chief Executive Officer or Managing Director) for resolution.
If such senior executives cannot resolve the matter within ten (10) business days, then such senior executive of Daewoong shall
have the final decision making authority on such matter, provided that any final determination made by such senior executive of
Daewoong shall be consistent with the terms of this Agreement, further provided that Daewoong shall not make any decision with
respect to the following critical issues without the consent of Ampio, such consent not to be unreasonably withheld or delayed:
(A) discontinue the Development of any Product; (B) initiate or discontinue any clinical trial; (C) unreasonably delay the process
of or cease to seek Regulatory Approval for any Product; (D) unreasonably delay or cancel the commercial launch of any Product;
and (E) remove any Product from the market, other than for safety reasons. For clarity, Ampio shall take the lead with respect
to all determinations relating to any clinical trials relating to any Product.

 

5.3 Costs of Governance. The Parties
agree that the costs incurred by each Party in connection with its participation at any meetings under this Article 5 shall be
borne solely by such Party, except that the costs of necessary translations and translators shall be divided equally between the
Parties.

 

6 Development

 

6.1 Development Plan.

 

(a) Within sixty (60) days after the Effective
Date (or such longer period of time as recommended by the JSC), the Parties will agree upon a development plan for the Development
of the Products in the Territory (the “Development Plan”). The Development Plan includes all clinical studies to be
performed for the Products, including those that are required for Regulatory Approval for the Products in the Territory. The Development
Plan shall also each specify the plans, timeline and budget for preparing the necessary Regulatory Filings and for obtaining Regulatory
Approvals for the Products in the Territory, which will provide for filing for Regulatory Approvals of the Products in the Territory
as soon as practicable following the Effective Date. Daewoong shall conduct the Development activities in accordance with the
then-current Development Plan (including the timelines set forth therein) and under the direction of the JSC.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 12	 

     

    

 

(b) From time to time during the Term, Daewoong
shall update and amend, as appropriate, the then-current Development Plan and submit such updated or amended Development Plan for
the JSC’s approval, such approval not to be unreasonably withheld or delayed. Once approved by the JSC, each updated or amended
Development Plan shall become effective and supersede the previous Development Plan as of the date of such approval.

 

6.2 Daewoong Development
Activities.

 

(a) Daewoong shall Develop the Products and
seek Regulatory Approval by timely and diligently conducting all Development activities under the Development Plan (the “Daewoong
Development Activities”).

 

(b) The status, progress and results of the
Development activities in the Territory shall be discussed at meetings of the JSC, and Daewoong shall provide the JSC with a written
report on the status and progress of such Development activities on a half-yearly basis at least five

 

(5) business days prior to each scheduled
JSC meeting. In addition, Daewoong shall make available to Ampio such information about such Development activities as may be reasonably
requested by Ampio from time to time.

 

6.3 Compliance.

 

(a) Daewoong agrees that in performing its obligations
under this Agreement: (i) it shall comply with all applicable Laws; and (ii) it will not employ or engage any person who has been
debarred by any Regulatory Authority, or, to such Party’s knowledge, is the subject of debarment proceedings by a Regulatory
Authority. Daewoong shall have the right to engage subcontractors for the performance of its obligations under the Development
Plan. Daewoong remains responsible for the performance of such subcontractor(s) and the engagement of such subcontractors shall
not relieve Daewoong from its obligations to comply with the terms and conditions of this Agreement.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 13	 

     

    

 

(b) Daewoong shall
maintain complete, current and accurate records of all work conducted by it under the Development Plan, and all data and
other Information resulting from such work. Daewoong shall cause the Sublicensees to maintain complete, current and accurate
records of all work conducted by such Sublicensees under the Development Plan, and all data and other Information resulting
from such work. Such records shall fully and properly reflect all work done and results achieved in the performance of the
Development activities in good scientific manner appropriate for regulatory purposes. Ampio shall have the right to review
all records maintained by Daewoong or such Sublicensees at reasonable times, upon Ampio’s written request.

 

(c) Daewoong shall document all preclinical
studies and clinical trials conducted by or for it in written study reports and shall provide Ampio with a summary of each such
report in English promptly after its completion.

 

6.4 Development Costs.
As between the Parties, Daewoong shall bear all Development Costs for the Development: (a) conducted by or for Daewoong and incurred
by Daewoong; or (b) conducted by Ampio for Daewoong at the written request of or with the written consent of Daewoong and incurred
by Ampio, in each case after the Effective Date in connection with the research, manufacture and Development (including development
of manufacturing processes for the Products and other matters relating to the chemistry, manufacture and controls of the Products)
of the Products in accordance with the Development Plan or the other provisions of this Agreement, as well as any other research,
manufacture and development of the Products by Daewoong.

 

7 Regulatory Matters

 

7.1 Daewoong Regulatory
Responsibilities.

 

(a) Subject to the termination of this Agreement,
Daewoong shall own all Regulatory Filings and Regulatory Approvals for the Products in the Territory, and shall be solely responsible
for preparing any and all Regulatory Filings for the Products in the Territory at its sole expense in accordance with the Daewoong
Development Plan, with the direction of the JSC and subject to the terms of this Article 7. Ampio shall assist Daewoong or its
Sublicensees as they may reasonably request in connection with the preparation and filing of such Regulatory Filings, at Daewoong’s
or its Sublicensees’ reasonable request and expense.

 

(b) Daewoong shall keep Ampio informed of regulatory
developments specific to Products throughout the Territory, and Ampio shall have the right to contribute to the regulatory plans
and strategies for the Products in the Territory.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 14	 

     

    

 

(c) Daewoong shall, and shall ensure
that its Sublicensees will, lead discussions with any Regulatory Authority related to any Development of any Products.
Daewoong will, and will cause its Sublicensees to, inform Ampio of any such discussions in advance to the extent practicable,
and Daewoong will, and will ensure that its Sublicensees will, reasonably consider any input from Ampio in preparation for
such discussions.

 

(d) Daewoong shall, and
shall ensure that its Sublicensees will, be responsible to ensure, at its sole expense, that the Development, manufacture and
Commercialization of the Products in the Territory are in compliance with all applicable Laws, including without limitation all
rules and regulations promulgated by any of the Regulatory Authorities in the Territory. Specifically and without limiting the
foregoing, Daewoong shall, and shall ensure that its Sublicensees will, file all compliance filings, certificates and safety reporting
(subject to Section 7.2(a)) in the Territory at its sole expense.

 

(e) to the extent permitted by the applicable
Regulatory Authority and as requested by Ampio, Daewoong shall, and shall ensure that its Sublicensees will, allow representatives
of Ampio to participate in any scheduled conference calls and meetings between Daewoong or its Sublicensees and the Regulatory
Authority at Ampio’s expense. If Ampio elects not to participate in such calls or meetings, Daewoong shall, and shall ensure
that its Sublicensees will, provide Ampio with written summaries of such calls and meetings in English as soon as practicable after
the conclusion thereof.

 

(f) with respect to all Regulatory Filings,
Daewoong shall, and shall ensure that its Affiliates and Sublicensees will: (i) submit only data and information that are free
from fraud or material falsity; (ii) not use bribery or the payment of illegal gratuities in connection with its Regulatory Filings
for the Products; and (iii) submit only data and information that are accurate and reliable in all material respects for purposes
of supporting Regulatory Approval.

 

7.2 Adverse Events.

 

(a) Within one (1) year prior to the planned
first Regulatory Approval of the Products in the Territory, the Parties shall discuss in good faith and enter into a pharmacovigilance
and adverse event reporting agreement setting forth the worldwide pharmacovigilance procedures for the Parties with respect to
the Products, such as safety data sharing, adverse events reporting and prescription events monitoring (the “Pharmacovigilance
Agreement”). Such Pharmacovigilance Agreement shall govern the global pharmacovigilance procedures to be agreed upon by Daewoong,
Ampio, Ampio Licensees and the commercial partners of each Party.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 15	 

     

    

 

(b) Prior to the execution of such Pharmacovigilance
Agreement, the Parties agree to coordinate the pharmacovigilance procedures in connection with the Development of the Products,
and Daewoong shall submit to Ampio all safety information and reporting in a manner that meets the reporting requirements in the
Retained Territory. Each Party shall notify the other Party within twenty-four (24) hours of such Party’s learning of any
Serious Adverse Events (as defined below) that is attributed to or potentially attributable to the use of the Products. Each Party
shall also provide the other Party, on an annual basis and more frequently as reasonably requested by the other Party, a summary
report of Adverse Events (as defined below), as well as those Serious Adverse Events that are not attributable to the use of the
Products. As used herein, unless defined differently by the FDA, “Adverse Events” means any side effect, injury, toxicity
or sensitivity reaction, or any unexpected incident, and the severity thereof, whether or not determined to be attributable to
any Product, and “Serious Adverse Events” means an Adverse Event which results in death, is immediately life-threatening,
results in persistent and significant disability/incapacity or requires in-patient hospitalization or prolongation of existing
hospitalization.

 

(c) After the execution of the Pharmacovigilance
Agreement, the Parties shall comply with such Pharmacovigilance Agreement with respect to all aspects of pharmacovigilance activities
with respect to the Products, and Section 7.2(b) above shall be of no further effect.

 

7.3 No Harmful Actions. If either Party
believes that the other Party, as the case may be, is taking or intends to take any action with respect to the Product that could
reasonably be expected to have a material adverse impact upon the regulatory status of the Product in the Retained Territory or
the Territory, such Party shall have the right to bring the matter to the attention of the JSC. Without limiting the foregoing,
unless the Parties otherwise agree: (a) Daewoong shall not communicate with any Regulatory Authority having jurisdiction in the
Retained Territory, unless so ordered by such Regulatory Authority, in which case Daewoong shall provide immediately to Ampio notice
of such order; and (b) Daewoong shall not submit any Regulatory Filings or seek Regulatory Approvals for the Products in the Retained
Territory.

 

7.4 Notification of Threatened Action.
Each Party shall immediately notify the other Party of any information it receives regarding any threatened or pending action,
inspection or communication by or from any party, including, without limitation, a Regulatory Authority, which may affect the safety
or efficacy claims of a Product or the continued marketing of a Product. Upon receipt of such information, the Parties shall consult
with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 16	 

     

    

 

7.5 Data Exchange and Use. This
Section 7.5 shall not apply to any pharmacovigilance data (which is addressed in Section 7.2). Daewoong shall, and shall
ensure that its Sublicensees will, provide Ampio with copies of all final submissions and correspondence to and from all
Regulatory Authorities relating to the Products in the Field within seven (7) days of submission or receipt, as applicable,
and shall, and shall ensure that its Sublicensees will, provide Ampio a summary of each significant submission (such as
application for approval for clinical trials, Regulatory Approval and fast track or orphan drug designation, the protocol for
clinical trials and any modifications thereof) in English as soon as practicable but in any event within ten (10) business
days after such submission. Each Party shall permit the other Party to access, and shall provide the other Party with rights
to reference and use in association with the Products in the Field, all of its, its Affiliates’, and its or their
licensees’ and Sublicensees’ regulatory, preclinical and clinical data documentation, Regulatory Filings, and
Regulatory Approvals with respect to the Products in the Field.

 

7.6 Remedial Actions.
Each Party will, and will ensure that its Affiliates and Sublicensees will, notify the other Party immediately, and promptly confirm
such notice in writing, if it obtains information indicating that a Product may be subject to any recall, corrective action or
other regulatory action with respect to a Product taken by virtue of applicable Law in the Territory (a “Remedial Action”).
The Parties (or Daewoong’s Sublicensees and Ampio), as the case may be, will assist each other in gathering and evaluating
such information as is necessary to determine the necessity of conducting a Remedial Action. Daewoong shall, and shall ensure that
its Affiliates and Sublicensees will, maintain or have maintained adequate records to permit the Parties to trace the manufacture
of the Product and the distribution and, to the extent feasible, the use of the Product. In the event Daewoong or its any Sublicensee
determines that any Remedial Action with respect to a Product in the Field in the Territory should be commenced or Remedial Action
is required by any Regulatory Authority having jurisdiction over the matter, Daewoong will, and will ensure that its Sublicensees
will, as the case may be, control and coordinate all efforts necessary to conduct such Remedial Action. In the event Ampio determines
that any Remedial Action with respect to a Product outside the Field in the Territory should be commenced or Remedial Action is
required by any Regulatory Authority having jurisdiction over the matter, Ampio will control and coordinate all efforts necessary
to conduct such Remedial Action. For clarity, as between the Parties, Ampio shall have sole discretion with respect to any matters
relating to any Remedial Action in the Retained Territory. The cost and expense of a Remedial Action arising from the development,
manufacture or commercialization of the Product in the Field in the Territory shall be borne solely by Daewoong or its Sublicensees.

 

7.7 Rights of Reference to
Regulatory Documentation. Each Party hereby grants to the other Party a right of reference to all Regulatory
Documentation filed by such Party for the Products subject to the scope of the licenses granted hereunder, including, for the
avoidance of doubt, all such Regulatory Documentation filed by Ampio for Regulatory Approval of the Products in the Retained
Territory and all supplemental filings related thereto, and all “Certificate(s) of Pharmaceutical Product” and/or
“Certificate(s) of Free Sales” resulting from Regulatory Approval of such Products, solely for the purpose of
seeking, obtaining and maintaining Regulatory Approvals for, and the Commercialization of, the Product in the Territory and
the Field, consistent with the roles of the Parties set forth in this Agreement. In addition, Daewoong hereby grants to Ampio
a right of reference to all Regulatory Documentation filed by Daewoong in the Territory for the purpose of Ampio, its
Affiliates or any Ampio Licensees developing and obtaining and/or maintaining Regulatory Approvals anywhere in the world for
the Products in the Field in the Retained Territory.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 17	 

     

    

 

8 Commercialization

 

8.1 Overview of Commercialization
in the Territory. Daewoong, its Affiliates and its Sublicensees will have responsibility for all decisions related to and implementation
of Commercialization activities, including but not limited to price, reimbursement and distribution, for the Products in the Territory,
at its sole expense. Daewoong will prepare and submit to the JSC a commercialization plan no later than six (6) months prior to
the anticipated date of Regulatory Approval for the first Product in the Territory (the “Commercialization Plan”).
Such Commercialization Plan shall incorporate the commercialization diligence requirements set forth below. Daewoong will update
such Commercialization Plan on a yearly basis and will provide quarterly reports to Ampio describing Daewoong’s progress
against such Commercialization Plan. Daewoong shall use Commercially Reasonable Efforts to maximize sales of the Products throughout
the Territory in accordance with the Commercialization Plan. Furthermore, Ampio and Daewoong agree that the initial commercial
price for a Tramadol Only Product shall be US$5.00 per tablet, and if the parties decide the Net Sales needs to be adjusted, the
parties shall discuss in good faith with the JSC. For clarification, the commercial price means the cost of medicine that the patient
pays the pharmacy for a Tramadol Only Product.

 

8.2 Trademark. Daewoong
shall have the right to brand the Products using Daewoong related trademarks and any other trademarks and trade names it determines
appropriate for the Products in consultation with Ampio (“Product Marks”). Daewoong shall own all rights in the Product
Marks and register and maintain the Product Marks in the countries and regions it determines reasonably necessary. Notwithstanding
any provisions in this Agreement, Daewoong shall be the exclusive sole owner for the Product Marks even after the termination of
this Agreement for whatever reasons.

 

9 Manufacture and Supply;
Payment for Products

 

9.1 General Supply Terms. Ampio shall,
itself or through one or more Third Party contract manufacturers, manufacture the Products in finished form in unlabeled containers
in accordance with the terms of Section 9, including the performance of all manufacturing process development and scale-up for
the Products (and associated regulatory activities), and shall supply to Daewoong, and Daewoong shall purchase from Ampio, all
of Daewoong and its Affiliates’ and its/their Sublicensees’ requirements of the Products for Development and Commercial
activities as and to the extent set forth in this Agreement and the Supply Agreement. Daewoong shall be responsible for labelling
and packaging all Products supplied by Ampio to Daewoong under this Agreement and the Supply Agreement.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 18	 

     

    

 

9.2 Supply Agreement. Within sixty (60)
days after the Effective, the Parties shall enter into a supply agreement and quality agreement governing the supply of Products
to Daewoong for clinical and commercial use, as well as the quality control and quality assurance procedures thereon (collectively
the “Supply Agreement”) and any other operational agreements and procedures as deemed necessary by the Parties for
such supply of the Products. The terms of such Supply Agreement shall be negotiated in good faith by the Parties.

 

9.3 Payment and Pricing. The Supply Agreement
shall provide for payment by Daewoong for Product supplied by Ampio in the manner prescribed below.

 

(a) Tramadol-Only Product.

 

(i) Within thirty (30)
days after supply by Ampio to Daewoong, its Affiliates or its Sublicensees of any Tramadol-Only Product, Daewoong shall pay to
Ampio an amount equal to Transfer Price.

 

(ii) Within thirty (30)
days after the end of each calendar quarter, Daewoong shall pay to Ampio an amount equal to the difference between (x) 25% of the
Net Sales of such Tramadol-Only Product minus (y) the Transfer Price.

 

(b) Combination Product. The
transfer price for the Combination Product will be determined at a later date via the Supply Agreement.

 

9.4 Reports; Records.
During the term of this Agreement after First Commercial Sale of the first Product, Daewoong shall furnish or cause to be furnished
to Ampio within thirty (30) days after the end of each calendar quarter (each a “Reporting Period”) a written report
or reports (the “Sales Report”) covering the applicable Reporting Period and containing the following information:

 

(a) the Net Sales of Products
in the Territory during the Reporting Period;

 

(b) the royalties, payable
in U.S. Dollars, which shall have accrued hereunder in respect to such Net Sales;

 

(c) withholding taxes, if
any, required by Law to be deducted in respect of such royalties; and

 

(d) the exchange rates used
in determining the amount of U.S. Dollars.

 

9.5 Exchange Rates; Reports.
With respect to sales of Product invoiced in U.S. Dollars, the Net Sales and royalty payable shall be expressed in such
currency as it is. With respect to sales of Product invoiced in a currency other than U.S. Dollars, the Net Sales and royalty
payable shall be expressed in the domestic currency of the Republic of Korea together with the U.S. Dollars equivalent of the
royalty payable, calculated using the average exchange rates posted in The Financial Times published on the first and
last days of each month within each calendar quarter (each a “Reporting Period”). Sales Reports shall be due
thirty (30) days following the close of each respective Reporting Period. Daewoong and its Affiliates and Sublicensees shall
keep legible, verifiable and accurate records in sufficient detail to enable the royalties payable hereunder to be determined
and substantiated.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 19	 

     

    

 

9.6 Withholding Tax.
Daewoong shall deduct any withholding taxes and other statutory duties from all payments set forth herein and pay them to the proper
tax authorities if required by applicable Law. Daewoong shall maintain official receipts related to any withholding taxes and forward
copies of such receipts to Ampio. The Parties will exercise their commercially reasonable efforts to ensure that any withholding
taxes imposed are reduced as far as possible under the provisions of the current or any future double taxation agreement between
the Republic of Korea and the United States of America. If, according to Laws applied to the Parties, this reduction requires a
certificate of tax exemption, and in order to achieve such reduction, each Party shall cooperate with the other Party with applicable
legal procedure and shall provide the other Party with the claim for a certificate of tax exemption in respect of royalties paid
on the official form containing a certification of residence of the competent tax authority and other appropriate documents.

 

9.7 Audit Rights. Ampio shall have the
right to have an independent public accounting firm of its own selection, except one to whom Daewoong, its Affiliates or Sublicensees
may have reasonable objection, and at Ampio’s own expense (except if the result of such audit results in an underpayment
exceeding five percent (5%) of the payments that were paid to Ampio), examine the relevant books and records of account of Daewoong
and any of its Affiliates and Sublicensees during reasonable business hours upon reasonable prior written notice to Daewoong and
not more often than once each calendar year, for not more than two (2) previous years, to determine whether appropriate payment
have been made to Ampio hereunder. Ampio may exercise such right until the end of one (1) year after the termination or expiration
of this Agreement. Daewoong shall promptly pay to Ampio the full amount of any undisputed underpayment. If the amount of the underpayment
is greater than five percent (5%) on an annualized basis, Daewoong shall pay interest on that amount that is in excess of five
percent (5%) at the rate of LIBOR plus two percent (2%) per year, compounding annually from the date payment was due. Ampio shall
promptly pay to Daewoong the full amount of any overpayment. Such public accounting firm shall treat as confidential, and shall
not disclose to Ampio, any information other than information which could otherwise be given to Ampio pursuant to any provision
of this Agreement, all of which shall be treated as Confidential Information of Daewoong hereunder.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 20	 

     

    

 

9.8 Recalls and Voluntary
Withdrawals. The Parties shall exchange their internal standard operating procedures (“SOPs”) for conducting
product recalls reasonably in advance of the First Commercial Sale of Product in the Territory, and shall discuss and resolve
any conflicts between such SOPs and issues relating thereto promptly after such exchange. If either Party becomes aware of
information relating to any released Product that indicates that a unit or batch of Product may not conform to the
specifications thereof, or that potential adulteration, misbranding, and/or other issues have arisen that relate to the
safety or efficacy of such released Product, it shall promptly so notify the other Party. To the extent Daewoong requires
such information to comply with applicable Laws or to determine whether to conduct a recall, Ampio shall promptly disclose to
Daewoong any CMC Information related to such nonconformance, adulteration, misbranding or other related issue. Daewoong shall
have the right, at its expense (except as provided herein), to control any Product recall, field correction, or withdrawal of
any released Product in the applicable jurisdiction in the Territory. Ampio shall have the right, at its expense, to control
any Product recall, field correction, or withdrawal of any released Product in the Retained Territory. Ampio shall be
responsible for all costs incurred for any recall, field correction, or withdrawal of any released Product for the Territory
to the extent such event of recall, field correction, or withdrawal is due to the material breach by Ampio of this Agreement
or the Supply Agreement. Daewoong shall be responsible for all other costs incurred for any recall, field correction, or
withdrawal of any released Product for the Territory. The procedures and consequences of such recalls shall be defined in the
Supply Agreement. The Party having the right to control such recall pursuant to this Section 9.8 may, at its sole discretion,
take appropriate courses of action, which shall be consistent with the internal SOPs of such Party; provided, however, that
such controlling Party shall promptly notify the other Party of any recall action being considered and where
practicable, consider the views of the non-controlling Party prior to taking any recall action. Daewoong shall maintain
complete and accurate records of any recall according to its then current SOPs in the Territory for such periods as may be
required by applicable Laws, but in no event for less than three (3) years.

 

9.9
Payment. Any invoice will be issued by Ampio together with the delivery of the Products to Daewoong and shall be paid by
Daewoong within thirty (30) days upon receipt by Daewoong of such invoice and acceptance by Daewoong of the applicable Product
shipment by wire transfer on a bank account designated by Ampio. All payments to Ampio shall be in US Dollars.

 

10 Representations, Warranties
and Covenants; Disclaimer

 

10.1 No Representation of Success. Ampio
does not warrant that Daewoong can successfully develop, obtain Regulatory Approvals for, or market the Products in the Territory
by using and relying upon the Ampio Patents, the Ampio Know-How and the Ampio Regulatory Documentation supplied by Ampio hereunder
and further that, except as expressly provided in Section 10.2, the Ampio Patents, the Ampio Know-How and the Ampio Regulatory
Documentation has not any defect.

 

10.2 Ampio Representations,
Warranties and Covenants. Ampio covenants, and represents and warrants to Daewoong as of the Effective Date, that:

 

(a) Ampio is a corporation duly organized, validly
existing and in good standing under the laws of the jurisdiction in which it is incorporated.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 21	 

     

    

 

(b) Ampio has full right and authority
to use the Ampio Patents, the Ampio Know-How and the Ampio Regulatory Documentation and to enter into this Agreement and to
grant the licenses to Daewoong as herein described.

 

(c) This Agreement has been duly authorized
by all requisite corporate action, and when executed and delivered will become a valid and binding contract of Ampio enforceable
against Ampio in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and other
Laws affecting creditors’ rights generally from time to time if effect, and to general principles of equity.

 

(d) The execution, delivery and performance
of this Agreement does not and will not conflict with any other agreement, contract, instrument or understanding, oral or written,
to which Ampio is a party, or by which it is bound, nor will it violate any Law applicable to Ampio.

 

(e) All necessary consents, approvals and authorizations
of all regulatory and governmental authorities and other persons or entities required to be obtained by Ampio in connection with
the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained.

 

(f) Ampio has not granted as of the Effective
Date, and will not grant during the term of this Agreement, any licenses to any Affiliate or Third Party under the Ampio Patents,
Ampio Know-How or Ampio Regulatory Documentation which would conflict with the licenses granted to Daewoong hereunder.

 

10.3 Daewoong Representations
and Warranties. Daewoong covenants, and represents and warrants to Ampio as of the Effective Date, that:

 

(a) Daewoong is a corporation duly organized,
validly existing and in good standing under the laws of jurisdiction in which it is incorporated and it has full right and authority
to enter into this Agreement and to accept the rights and licenses granted as herein described.

 

(b) This Agreement has been duly authorized
by all requisite corporate action, and when executed and delivered will become a valid and binding contract of Daewoong enforceable
against Daewoong in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and other
Laws affecting creditors’ rights generally from time to time if effect, and to general principles of equity.

 

(c) The execution,
delivery and performance of this Agreement does not and will not conflict with any other agreement, contract, instrument or
understanding, oral or written, to which Daewoong is a party, or by which it is bound, nor will it violate any Law applicable
to Daewoong.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 22	 

     

    

 

(d) All necessary consents, approvals and authorizations
of all regulatory and governmental authorities and other persons or entities required to be obtained by Daewoong in connection
with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained.

 

(e) Daewoong has not as of the Effective Date
knowingly performed any acts that are inconsistent with the terms and purposes of this Agreement.

 

(f) Daewoong warrants that any sublicense granted
hereunder by Daewoong or any Sublicensee shall be subject to the terms and conditions of this Agreement.

 

(g) Daewoong has undertaken the investigation
and has evaluated documents and information as practically it has deemed necessary to enable it to make an informed and intelligent
decision with respect to the execution, delivery and performance of this Agreement. Daewoong agrees to enter into this Agreement
in the terms and conditions herein on the Effective Date based upon its own inspection, examination and determination with respect
thereto as to all matters, and without reliance upon any express or implied representations or warranties of any nature made by
or on behalf of or imputed to Ampio or their Affiliates, except as expressly set forth in this Agreement. Without limiting the
generality of the foregoing, and except as expressly set forth in this Agreement, Daewoong acknowledges that Ampio is making no
representation or warranty with respect to any Ampio Know-How, Ampio Patent or Ampio Regulatory Documentation licensed to Daewoong
hereunder.

 

10.4 Limitation of Warranty.
EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTY, AND EACH PARTY HEREBY DISCLAIMS
ALL IMPLIED WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO ANY OF THE MATERIALS,
INFORMATION, SERVICES OR LICENSES PROVIDED PURSUANT TO THIS AGREEMENT.

 

10.5 Performance by
Affiliates. The Parties recognize that each Party may perform some or all of its obligations under this Agreement through Affiliates
and Third Party contractors provided, however, that each Party shall remain responsible and liable for the performance by its Affiliates
and Third Party contractors and shall cause its Affiliates and Third Party contractors to comply with the provisions of this Agreement
in connection with such performance.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 23	 

     

    

 

11 Intellectual Property

 

11.1 Ownership of Inventions;
Assignment. Each Party shall own all right, title, and interest in and to any inventions made solely by such Party’s
employees, agents, independent contractors and sublicensees in the course of conducting its activities under this Agreement during
the Term, together with all intellectual property rights therein, including any rights to applications or other protections for
any of the foregoing. The Parties shall jointly own all inventions made jointly by the employees, agents, independent contractors
or sublicensees of each Party, in accordance with joint ownership interests of co-inventors under U.S. patent laws (that is, each
Party shall have full rights to license, assign and exploit such joint inventions (and any patents arising therefrom) anywhere
in the world, without any requirement of gaining the consent of, or accounting to, the other Party), subject to the licenses granted
herein and subject to any other intellectual property held by such other Party; provided, however, that Daewoong shall not have
the right to practice any jointly owned invention in any activities related to a product that competes with the Product. The Parties
shall determine which Party will file, prosecute and maintain the Patents claiming or covering such jointly owned inventions. Inventorship
shall be determined in accordance with U.S. patent laws. Notwithstanding the foregoing, Daewoong agrees to assign and hereby assigns
and transfers to Ampio all of its right, title and interest in and to any such solely owned or jointly owned inventions that relate
to the composition of matter, manufacture or use of the Product (“Product Inventions”), and agrees to take, and to
cause its employees, agents, consultants and sublicensees to take, all further acts reasonably required to evidence such assignment
and transfer to Ampio, at Ampio’s reasonable expense. Daewoong hereby appoints Ampio as its attorney-in-fact to sign such
documents as Ampio deems necessary for Ampio to obtain ownership and to apply for, secure, and maintain patent or other proprietary
protection of such Product Inventions if Ampio is unable, after reasonable inquiry, to obtain Daewoong’s (or its employee’s
or agent’s) signature on such a document. Daewoong hereby waives, on behalf of itself, its parent, subsidiaries, Affiliates
and partners as well as all of its employees and independent contractors, any rights of first refusal it, he, or she may have with
respect to any contemplated technology transfer, in whole or in part, of the Product Inventions or any related patent, patent application,
copyright or copyright application related thereto as well as any right accorded to it, him, or her, by statute or otherwise, to
use any Product Invention or any Patent or copyright related thereto. All Patents claiming or covering any Product Invention shall
be referred to herein as “Product Patents.”

 

11.2 Disclosure of Inventions. Daewoong
shall, and shall cause its Third Party Subcontractors, Affiliates and Sublicensees to, promptly disclose to Ampio any invention
disclosures, or other similar documents, submitted to it by its employees, agents, consultants or independent contractors describing
inventions that may be Product Inventions, and all Information relating to such inventions to the extent necessary for the preparation,
filing and maintenance of any Patent with respect to such invention.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 24	 

     

    

 

11.3 Prosecution of Patents.

 

(a) Ampio shall have the sole right to prepare,
file, prosecute and maintain the Ampio Patents at Ampio’s own costs and expenses. If Ampio determines in its sole discretion
to abandon all claims in any Ampio Patent in the Territory, then Ampio shall provide Daewoong with written notice of such determination
within a period of time reasonably necessary to allow Daewoong to determine its interest in such Ampio Patent(s). In the event
Daewoong provides written notice expressing its interest in obtaining such Ampio Patent(s), Ampio shall assign and transfer to
Daewoong the ownership of, and interest in, such Ampio Patent(s) in the Territory, such transfer to be at Daewoong’s reasonable
expense (but without payment to Ampio). Thereafter, Daewoong shall bear all of the costs of preparation, filing, prosecution and
maintenance of such assigned and transferred Patents, which shall not be treated as Ampio Patents and shall be treated as Daewoong
Patents, and Daewoong may prosecute such Daewoong Patents at its sole discretion; provided, however, in the event that Daewoong
decides to abandon or not maintain any such Patent(s), Daewoong shall promptly provide Ampio with written notice of such decision.

 

(b) Daewoong shall be solely responsible to file,
prosecute and maintain Daewoong Patents. With respect to Daewoong Patents under which Ampio receives a license pursuant to Section
2.2 hereof, Daewoong shall provide Ampio reasonable opportunity to review and comment on such prosecution efforts regarding such
Daewoong Patents, including by providing Ampio with a copy of material communications from any patent authority in the Territory
regarding such Daewoong Patent(s), and by providing drafts of any material filings or responses to be made to such patent authorities
in advance of submitting such filings or responses. Daewoong shall reasonably consider such comments by Ampio in connection with
the prosecution of Daewoong Patents.

 

11.4 Patent Term Extensions in the
Territory. The JSC will discuss and recommend for which, if any, of the Patents within the Ampio Patents and Daewoong
Patents in the Territory the Parties should seek Patent Term Extensions in the Territory. Ampio, in the case of the Ampio
Patents, and Daewoong in the case of the Daewoong Patents, shall have the final decision-making authority with respect to
applying for any such Patent Term Extensions in the Territory, and will act with reasonable promptness in light of the
development stage of the Product to apply for any such Patent Term Extensions, where it so elects; provided, however, that if
only one such Patent can obtain a Patent Term Extension, then the Parties will consult in good faith to determine which such
Patent should be the subject of efforts to obtain a Patent Term Extension, and in any event Ampio’s decision on such
matter will control in the case of a disagreement. The Party that does not apply for an extension hereunder will cooperate
fully with the other Party in making such filings or actions, for example and without limitation, by making available all
required regulatory data and information and executing any required authorizations to apply for such Patent Term Extension.
All expenses incurred in connection with activities of each Party with respect to the Patent(s) for which such Party seeks
Patent Term Extensions pursuant to this Section 11.4 shall be entirely borne by such Party.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 25	 

     

    

 

11.5 Infringement of Patents
by Third Parties.

 

(a) Each Party shall promptly notify the other
Party in writing of any existing or threatened infringement in the Territory of the Ampio Patents or Daewoong Patents of which
it becomes aware, and shall provide all evidence in such Party’s possession demonstrating such infringement.

 

(b) If a Third Party infringes any Ampio Patent
in the Territory by making, using, importing, offering for sale or selling the Product or a competitive product in the Field (a
“Product Infringement”), each Party shall share with the other Party all Information available to it regarding such
alleged infringement. Ampio shall have the sole and exclusive right, but not the obligation, to bring an appropriate suit or other
action against any person or entity engaged in such Product Infringement in the Territory. Daewoong shall provide to Ampio reasonable
assistance in such enforcement, at Ampio’s request and expense, including joining such action as a party plaintiff if required
by applicable Laws to pursue such action. Ampio shall keep Daewoong regularly informed of the status and progress of such enforcement
efforts, shall reasonably consider Daewoong’s comments on any such efforts, and shall seek consent of Daewoong in any important
aspects of such enforcement, including determination of litigation strategy and filing of important papers to the competent court,
which shall not be unreasonably withheld or delayed. Each Party shall bear all of its own internal costs incurred in connection
with its activities under this Section 11.5(b). Daewoong shall be entitled to separate representation in such matter by counsel
of its own choice and at its own expense, but Daewoong shall at all times cooperate fully with Ampio bringing such action.

 

(c) If Ampio, in its sole discretion,
determines not to exercise its right to bring an action against Product Infringement in the Territory, Daewoong shall be
entitled to do so. Ampio shall provide to Daewoong reasonable assistance in such enforcement, at Daewoong’s request and
expense, including joining such action as a party plaintiff if required by applicable Laws to pursue such action. Daewoong
shall keep Ampio regularly informed of the status and progress of such enforcement efforts, shall reasonably consider
Ampio’s comments on any such efforts, and shall seek consent of Ampio in any important aspects of such enforcement,
including determination of litigation strategy and filing of important papers to the competent court, which shall not be
unreasonably withheld or delayed. Each Party shall bear all of its own internal costs incurred in connection with its
activities under this Section 11.5(c). Ampio shall be entitled to separate representation in such matter by counsel of its
own choice and at its own expense, but Ampio shall at all times cooperate fully with Daewoong bringing such action.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 26	 

     

    

 

(d) For any and all infringement
of any Daewoong Patent anywhere in the Territory, Daewoong shall have the sole and exclusive right, but not the obligation, to
bring, at Daewoong’s expense and in its sole control, an appropriate suit or other action against any person or entity engaged
in such infringement of the Daewoong Patent.

 

(e) Daewoong shall not settle any claim, suit
or action that it brought under this Section 11.5 involving Ampio Patents without the prior written consent of Ampio, which consent
shall not be unreasonably withheld or delayed; provided that Ampio shall have the sole discretion to withhold consent in the event
it determines that such settlement would restrict in any material respect the scope of the Ampio Patents or its rights or interests
therein.

 

(f) If either Party recovers monetary damages
from any Third Party in a suit or action brought hereunder with respect to Ampio Patents or Daewoong Patents, including in a settlement,
such recovery shall be allocated first to the reimbursement of any expenses incurred by the Parties in such litigation (including,
for this purpose, a reasonable allocation of expenses of internal counsel), and any remaining amounts shall be split as follows:
(i) the portion of such amounts that represents recovery for lost sales in the Territory shall be retained by Daewoong and treated
as Net Sales, on which Daewoong shall make a transfer price payment, and (ii) any remaining amounts shall be retained by the Party
bring such suit or action.

 

11.6 Infringement of Third
Party Rights in the Territory.

 

(a) If any Product used or sold by either
Party, its Affiliates, licensees or sublicensees becomes the subject of a Third Party’s claim or assertion of infringement
of a Patent granted by a jurisdiction within the Territory, the Party first having notice of the claim or assertion shall promptly
notify the other Party, the Parties shall agree on and enter into an “identity of interest agreement” wherein such
Parties agree to their shared, mutual interest in the outcome of such potential dispute, and thereafter, the Parties shall promptly
meet to consider the claim or assertion and the appropriate course of action.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 27	 

     

    

 

(b) Daewoong shall have the first
right, but not the obligation, to defend any such Third Party threatened or asserted claim of infringement of a Patent as
described in Section 11.6(a) above, at Daewoong’s expense. If Daewoong does not commence actions to defend such claim
within thirty (30) days after it receives notice thereof (or within thirty (30) days after it should have given notice
thereof to Ampio as required by Section 11.6(a)), then to the extent allowed by applicable Laws, Ampio shall have the right,
but not the obligation, to control the defense of such claim by counsel of its choice, at Ampio’s expense. The
non-defending Party shall reasonably cooperate with the Party conducting the defense of the claim or assertion, including, if
required to conduct such defense, furnishing a power of attorney.

 

(c) Each Party shall have the right to participate
or otherwise be involved in any such action controlled by the other Party, in each case at the participating Party’s sole
cost and expense. If a Party elects to so participate or be involved, the controlling Party shall provide the participating Party
and its counsel with an opportunity to consult with the controlling Party and its counsel regarding the prosecution of such action
(including reviewing the contents of any correspondence, legal papers or other documents related thereto), and the controlling
Party shall take into account reasonable requests of the participating Party regarding such enforcement or defense.

 

(d) Neither Party shall enter into any settlement
of any claim described in this Section 11.6 that affects the other Party’s rights or interests or the scope of any Ampio
Patent and/or Daewoong Patent in any material respect without such other Party’s written consent. Each Party shall have the
right to decline to defend or to tender defense of any such claim to the other Party upon reasonable notice, including if the other
Party fails to agree to a settlement that such Party proposes. If a Party desires to take a license under any applicable Third
Party intellectual property rights for the purpose of Developing or Commercializing the Product in the Field, then such Party shall
submit the terms of such license to the JSC for review and approval. Any such license agreement will require the applicable Third
Party to grant licenses to both Daewoong and Ampio for performing their respective obligations and exercising their respective
rights in the Territory under this Agreement, will contain a release of any liabilities accrued prior to the effective date of
such license agreement, and will be subject to the mutual agreement of the Parties.

 

11.7 Patent Marking.
Daewoong (or its Affiliate or Sublicensees) shall mark Product marketed and sold by Daewoong (or its Affiliate or Sublicensees)
hereunder with appropriate patent numbers or indicia.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 28	 

     

    

 

11.8 Patent Oppositions
and Other Proceedings.

 

(a) Daewoong shall be prohibited from initiating
or requesting any interference or opposition proceeding with respect to, or making, filing or maintaining any claim to challenge
the validity, infringement or enforceability of, any Ampio Patent.

 

(b) If either Party
desires to bring an opposition, action for declaratory judgment, nullity action, interference, declaration for
non-infringement, reexamination or other attack upon the validity, title or enforceability of a Patent owned or controlled by
a Third Party and having one or more claims that covers the Product, or the use, sale, offer for sale or importation of the
Product (except insofar as such action is a counterclaim to or defense of, or accompanies a defense of, a Third Party’s
claim or assertion of infringement under Section 11.6, in which case the provisions of Section 11.6 shall govern), such Party
shall so notify the other Party and the Parties shall promptly confer to determine whether to bring such action or the manner
in which to settle such action. Daewoong shall have the exclusive right, but not the obligation, to bring at its own expense
and in its sole control any such action in the Territory. If Daewoong does not bring such an action in the Territory, within
ninety (90) days of notification thereof pursuant to this Section 11.8(b) (or earlier, if required by the nature of the
proceeding), then Ampio shall have the right, but not the obligation, to bring, at Ampio’s sole expense, such action.
The Party not bringing an action under this Section 11.8(b) shall be entitled to separate representation in such proceeding
by counsel of its own choice and at its own expense, and shall cooperate fully with the Party bringing such action. Any
awards or amounts received in bringing any such action shall be retained by the Party initiating such action.

 

(c) If any Ampio Patent
or Daewoong Patent or Patent Term Extension related thereto becomes the subject of any proceeding commenced by a Third Party within
the Territory in connection with an opposition, reexamination request, action for declaratory judgment, nullity action, interference
or other attack upon the validity, title or enforceability thereof (except insofar as such action is a counterclaim to or defense
of, or accompanies a defense of, an action for infringement against a Third Party under Section 11.5, in which case the provisions
of Section 11.5 shall govern), then the Party responsible for filing, preparing, prosecuting and maintaining such Patent or Patent
Term Extension as set forth in Sections 11.3 or 11.4 hereof shall control such defense at its own cost and expense. The controlling
Party shall permit the non-controlling Party to participate in the proceeding to the extent permissible under applicable Laws,
and to be represented by its own counsel in such proceeding, at the non-controlling Party’s expense. If either Party decides
that it does not wish to defend against such action, then the other Party shall have the right to assume defense of such Third-Party
action at its own expense. Any awards or amounts received in defending any such Third-Party action shall be allocated between
the Parties as provided in Section 11.5(f).

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 29	 

     

    

 

11.9 Compendial Listing and Register of
Exclusive License. Upon request of Daewoong, Ampio shall cooperate with Daewoong to (i) file appropriate information with the
applicable Regulatory Authority listing any Ampio Patents in the patent listing source in the Territory that is equivalent or similar
to the Orange Book in the U.S., if any, and (ii) register Daewoong’s license granted hereunder to the applicable Regulatory
Authority, a patent and trademark office or other relevant governmental agency or offices in the Territory, if any.

 

12 Confidentiality/Publications

 

12.1 Confidentiality.
Subject to any other provisions of this Agreement, each Party (the ”Receiving Party”), for itself and its Affiliates
and their (direct and indirect) licensees and Sublicensees, agrees that it shall, during the term of this Agreement and for a period
of five (5) years thereafter or ten (10) years from the Effective Date, whichever is longer, (i) hold in confidence using not less
than the efforts such Receiving Party uses to maintain in confidence its own proprietary information of similar kind and value
the Confidential Information received before or after the Effective Date from the other Party (the “Disclosing Party”),
(ii) not disclose such Confidential Information to any Third Party, except for those disclosures expressly permitted in this Section
12 below, and (iii) not use such Confidential Information for any purpose other than the purposes expressly permitted by this Agreement,
without first obtaining the prior written consent of the Disclosing Party, except as follows:

 

(a) such Confidential Information is a part
of the public domain, or is known to the Receiving Party or any of its Affiliates without any obligation to keep it confidential,
prior to its disclosure by the Disclosing Party to the Receiving Party hereunder; or

 

(b) such Confidential Information becomes a
part of the public domain after its disclosure by the Disclosing Party to the Receiving Party hereunder without any breach by the
Receiving Party of this Agreement; or

 

(c) such Confidential Information which the
Receiving Party can demonstrate that it has been independently developed either prior to its disclosure by the Disclosing Party
to the Receiving Party hereunder or without the use of Confidential Information of the Disclosing Party; or

 

(d) such Confidential Information
is disclosed to the Receiving Party by a Third Party who has the right to make such disclosure; or

 

(e) such Confidential Information
is required to be disclosed by Law.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 30	 

     

    

 

 

12.2 Authorized Disclosure. The Receiving
Party may disclose Confidential Information belonging to the Disclosing Party to the extent (and only to the extent) such disclosure
is for a permitted purpose and is reasonably necessary in the following instances:

 

(a) filing or prosecuting Patents;

 

(b) as part of or in support of Regulatory
Filings (provided that such Party has the right to use the Confidential Information for such purpose under Section 2.1;

 

(c) in prosecuting or defending
litigation;

 

(d) in order to comply with applicable non-patent
Laws (including the rules and regulations of the Securities and Exchange Commission (the ”SEC”) or any other national
securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure
is necessary for such compliance; and

 

(e) disclosure, solely on a “need to
know basis”, to Affiliates, potential and existing collaborators (including Sublicensees), permitted acquirers or assignees
under Section 21, subcontractors, investment bankers, investors and lenders, and their and each of the Parties’ respective
directors, employees, contractors and agents, each of whom prior to disclosure must be bound by written obligations of confidentiality
and non-use no less restrictive than the obligations set forth in this Section 12 (other than potential and existing investors
and lenders of Daewoong, with respect to which Daewoong shall use commercially reasonable efforts to be so bound); provided, however,
that the Receiving Party shall remain responsible for any failure by any Third Party who receives Confidential Information pursuant
to this Section 12.2(e) to treat such Confidential Information as required under this Section 12.

 

If and whenever any Confidential Information is
disclosed in accordance with this Section 12.2, such disclosure shall not cause any such information to cease to be Confidential
Information except to the extent that such disclosure results in a public disclosure of such information (otherwise than by breach
of this Agreement). Where reasonably possible and other than with respect to Section 12.2(e), the Receiving Party shall notify
the Disclosing Party of the Receiving Party’s intent to make such disclosure pursuant to this Section 12.2 sufficiently prior
to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate in
keeping with the terms of this Agreement to protect the confidentiality of the subject Confidential Information.

 

12.3 Terms of this
Agreement. The Parties shall treat the terms of this Agreement as Confidential Information of both Parties.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 31	 

     

    

 

12.4 Relationship to Confidentiality Agreement.
This Agreement supersedes the Mutual CDA, provided that all “Information” disclosed or received by the Parties thereunder
shall be deemed “Confidential Information” hereunder and shall be subject to the terms and conditions of this Agreement.

 

12.5 Publications. If either Party wishes
to publish any information, data or results regarding Tramadol or Products in written, oral or other form in any scientific journals
or scientific conferences, a manuscript of the proposed publication shall first be sent to the other Party at least thirty (30)
days in advance of such publication for review. Unless the reviewing Party informs the other in writing during this thirty (30)
day period that the proposed publication must be delayed in order to protect a patentable invention or changed to avoid disclosure
of Confidential Information of the Reviewing Party, the other Party shall be free to publish such results without restriction.
In the event that a delay of the proposed publication is required, the other Party shall withhold such submission for publication
for one additional period, up to sixty (60) days, or such other period as the Parties may mutually agree.

 

13 Term and Termination

 

13.1 Term. This
Agreement shall become effective on the Effective Date. Unless sooner terminated in accordance with any other provision of this
Agreement, the term of this Agreement shall expire on the tenth anniversary of the date of the First Commercial Sale by Daewoong
of the first Product in the Territory (the “Initial Term”). Thereafter, this Agreement shall be automatically renewed
for successive periods of two (2) years. Either Party shall have the right to terminate this Agreement at the end of the Initial
Term or at the end of any two (2) year renewal term by sending to the other Party a written notice of such termination at least
ninety (90) days prior to the expiration of such Initial Term or renewal term as the case may be.

 

13.2 Termination by Either
Party. Notwithstanding the stipulation in Section 13.1, either Party may terminate this Agreement upon the occurrence of any
of the following itemized events:

 

(a) Such Party notifies the other Party of the
fact of material default or breach of any material provision in this Agreement by the notified Party, and the notified Party fails
to take corrective measures to mitigate or cure such default or breach within sixty (60) days from the date of notification; or

 

(b) The other Party files in any court
or agency pursuant to any statute or regulation pertaining to bankruptcy, solvency, or payment of debts, of any state or
country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a
receiver or trustee of such other Party or of its assets, or if such other Party shall be served with an involuntary petition
against it, filed in any insolvency proceeding, and such petition shall not be dismissed within sixty (60) days after the
filing thereof, or if such other Party shall be a party to its dissolution or liquidation, or if such other Party shall make
an assignment for the benefit of creditors.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 32	 

     

    

 

14 Effects of Termination
or Expiration

 

14.1 Survival. Expiration
or termination of this Agreement for any reason shall be without prejudice to:

 

(a) the obligations of confidentiality provided for
in Section 12 shall survive;

 

(b) the Parties’ right
to receive all payments accrued under this Agreement;

 

(c) Ampio’s right of
inspecting books and account of Daewoong and its Affiliates and Sublicensees pursuant to Article 9;

 

(d) the rights and ownership in any Patents,
Know-How and Regulatory Documentation the respective Party has obtained prior to expiration or termination of this Agreement;

 

(e) Ampio’s rights
provided for in Section 2.2 shall survive and be co-exclusive, perpetual, irrevocable, royalty-free and fully paid-up; and

 

(f) any other rights or remedies
which either Party may then or thereafter have hereunder or at law or in equity or otherwise.

 

In addition to the foregoing, the following
provisions shall survive expiration or termination of this Agreement for any reason and shall continue in full force and effect:
Sections 1, 2.4, 4, 6.4, 7, 10, 11, 12, 14 and 15-27. Unless otherwise provided in this Section 14 and elsewhere herein, the license
grants contained in Sections 2.1 (except as otherwise provided in Section 2.3(b)), and all other licenses and other rights and
obligations hereunder, shall terminate upon termination of this Agreement.

 

14.2 Adverse Termination
Consequences for Daewoong. Upon termination of this Agreement for any reason, Daewoong, its Affiliates and Terminated
Sublicensees shall cease use of the Ampio Patents, Ampio Know-How and the Ampio Regulatory Documentation. In addition,
Daewoong shall destroy or return (with confirmation letter to Ampio upon request) to Ampio any and all Ampio Know-How and
Ampio Regulatory Documentation in the possession of Daewoong, its Affiliates and Terminated Sublicensees, without delay, with
the exception that each of Daewoong and its Affiliates and Terminated Sublicensees may keep one copy for its legal files.
Furthermore, upon termination of this Agreement by Ampio under Section 13.2, Daewoong hereby grants to Ampio, effective only
upon such termination, a fully paid-up (except as provided below) worldwide non-exclusive license, with the right to
sublicense, under the Daewoong Patents, Daewoong Know How and Daewoong Regulatory Documentation, to develop, have developed,
make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import and have imported Tramadol
and/or Products.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 33	 

     

    

 

14.3 Inventory Sell-Off.
Upon termination of this Agreement for any reason, Daewoong shall notify Ampio of the amount of Tramadol and Products Daewoong
and its Affiliates and Sublicensees then have on hand, and, if they so wish, Daewoong and its Affiliates and Sublicensees shall
thereupon be permitted to sell that amount of Tramadol and Products.

 

14.4 Transfer of Regulatory
Approvals. Upon termination of this Agreement by Ampio under Section 13.2, Daewoong shall, and shall cause its Affiliates and
any Terminated Sublicensees to, upon Ampio’s request, transfer to Ampio and/or its Affiliates and/or any Third Party appointed
by Ampio (hereinafter referred to as “Transferee”) with reasonable assistance, excluding financial assistance, to the
extent permissible under the Laws of the Territory, the Regulatory Approvals which Daewoong or its Affiliates or Terminated Sublicensees
have with respect to the Products in the Territory, in each case subject to all licenses granted by any of them (whether or not
in effect) to any Surviving Sublicensees and further subject to the royalty obligations (if any) set forth in Section 14.2. Such
assistance shall include, among others, an authorization by Daewoong or its Affiliates or Terminated Sublicensees given to the
Transferee to access to the Regulatory Approvals filed by Daewoong or its Affiliates or Terminated Sublicensees with the Regulatory
Authorities with respect to the Products in the Territory (e.g., Regulatory Filings), the provision by Daewoong, if necessary,
to the Transferee of the Daewoong Know-How and such other acts which the Transferee may reasonably request Daewoong in order to
transfer such Regulatory Approvals with respect to the Products in the Territory, subject in all cases to such licenses held by
the Surviving Sublicensees.

 

15 Announcement

 

No public announcement concerning the existence
of or terms of this Agreement shall be made, either directly or indirectly, by any Party to this Agreement, except as may be required
by Law or as may be required for recording purposes or as permitted by Section 12.2, without first obtaining the written approval
of the other Party and agreement upon the nature and text of such announcement or disclosure. Other than with respect to Section
12.2(e), the Party desiring to make any such public announcement shall inform the other Party of the proposed announcement in reasonably
sufficient time prior to public release, and shall provide the other Party with a written copy thereof, in order to allow such
other Party to review, comment upon and approve such announcement, which such approval shall not be unreasonably withheld or delayed.
It is the intention of the Parties to issue a press release upon signing this Agreement.

 

16 Governing Law

 

The formation, validity and performance of this
Agreement shall be governed by and interpreted in accordance with the internal substantive laws of the State of Delaware, without
giving effect to any choice of law rules in the State of Delaware or elsewhere.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 34	 

     

    

 

17 Dispute Resolution

 

17.1 Organization Resolution. The
Parties will try to settle their differences amicably between themselves. In the event of any controversy or claim arising out
of or relating to any provision of this Agreement or the performance or alleged non-performance of a Party of its obligations
under this Agreement (“Dispute”), a Party may notify the other Party in writing of such Dispute. If the Parties are
unable to resolve the Dispute within sixty (60) days of receipt of the written notice by the other Party, such Dispute shall be
referred to a senior executive of Daewoong and Ampio, who will use their good faith efforts to resolve the Dispute within thirty
(30) days after it was referred to them. If the senior executives are unable to resolve the Dispute, the Parties shall refer the
Dispute to arbitration as provided for in Section 17.2.

 

17.2 Jurisdiction by Agreement. Any Dispute
that is not resolved as provided in Section 17.1, whether before or after termination of this Agreement, shall be submitted exclusively
for resolution to arbitration administrated by the International Chamber of Commerce (“ICC”) and be finally settled
in accordance with the Rules of International Conciliation and Arbitration of ICC. The arbitration shall be subject to the governing
law set forth in Section 16, shall be held in New York, New York, in front of a panel of three (3) arbitrators, shall be conducted
in the English language, shall be final and binding determination of the Dispute and not subject to judicial review, and shall
not include any award of damages expressly prohibited by Section 17.3, and judgment upon any award rendered by the arbitrators
may be entered in any court having jurisdiction over the liable Party. Except for Disputes the resolution of which require the
arbitration of material rights of any Third Party, this Section 17.2 shall be the exclusive remedy with respect to any Dispute
for either Party or their Affiliates, provided that this Section 17 shall not restrict the Parties’ rights to seek preliminary
injunctive relief before a court of any jurisdiction.

 

17.3 Consequential Damages.
Neither Party hereto will be liable for special, incidental, indirect, punitive, exemplary or consequential damages arising out
of this Agreement or performance of its obligations hereunder or the exercise of its rights hereunder, including lost profits,
anticipated profit, lost goodwill, lost revenue, lost contracts, and lost opportunity arising from or relating to any breach of
this Agreement, regardless of the causes of action or theories of liability alleged any notice of such damages. Nothing in this
Section 17.3 is intended to limit or restrict the indemnification rights or obligations of either Party under Section 20.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 35	 

     

    

 

18 Notices

 

18.1 Any notice required to be given under this
Agreement shall be given in the English language by sending such notices by postage-prepaid registered airmail or an internationally
recognized overnight courier service addressed to the other Party at the address listed below:

 

For Ampio:

 

Ampio Pharmaceuticals, Inc.

5445 DTC Parkway, Suite 925

Greenwood Village, Colorado 80111

Attention:
Bruce G. Miller and Don Wingerter

 

With a required copy to:

 

Goodwin Procter LLP

Exchange Place

53 State Street

Boston, Massachusetts 02109

Attn: Lawrence Wittenberg,
Esq.

 

For Daewoong:

 

Daewoong Pharmaceuticals Co., Ltd

163-3 Samsungdong,
Kangnam-gu

Seoul, Republic of Korea

 

Attention:

 

Either Party may notify the other Party of a different
address to receive the other Party’s notices in accordance with the manner described in this Section 18.

 

18.2 In the case where any notice is sent by airmail,
such notice shall be sent return receipt requested and is deemed to be received by the other Party upon endorsement, by an employee
or agent of the other Party of such receipt.

 

19 Force Majeure

 

19.1 Neither Party shall be liable for any failure
to perform as required by this Agreement if such failure is due to circumstances reasonably beyond the control of such Party, including
requisition or interference by any government, state or local authorities, war, riots, civil disturbances, terrorism, strikes or
other labour disputes, accidents, failure to secure required governmental approval, civil disorders or acts of aggression, acts
of God, energy or other conservation shortages, plague or other such occurrences (“Force Majeure”).

 

19.2 If and when any Party is hindered in its
performance of its obligations under this Agreement by reason of Force Majeure, the performance shall be suspended during, but
not longer than, the continuance of such circumstances.

 

19.3 Either Party hereto whose performance of
obligations has been hindered by reason of Force Majeure shall, to the extent possible, inform the other Party immediately, and
shall use reasonable efforts to overcome the effect of the Force Majeure.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 36	 

     

    

 

20 Indemnification and
Insurance

 

20.1 Ampio shall defend, indemnify and hold harmless
Daewoong and its Affiliates and Sublicensees, and their officers, directors, employees, agents, distributors and suppliers, and
their respective successors, assigns, heirs and representatives (collectively, ”Daewoong Indemnitees”) from and against
all liabilities, damages, losses, suits, proceedings, actions, claims, judgments and costs and expenses (including legal fees and
expenses) resulting from any Third Party claim made or suit brought (collectively, ”Losses”) to the extent the same
is arising from or related to:

 

(a) Ampio’s material breach of any term of
this Agreement (including any express representation or warranty made herein),

 

(b) the negligence, recklessness or willful misconduct
or fraud on the part of Ampio or any of its Affiliates, or Ampio Licensees or any of their respective officers, directors, employees,
agents, distributors and suppliers, or any of their respective successors, assigns, heirs or representatives with respect to Tramadol
or Products supplied by Ampio or in the performance of Ampio’s obligations or exercise of Ampio’s rights under this
Agreement,

 

(c) any actual or alleged violation of Law
(other than any patent or other intellectual property Laws) in the performance of Ampio’s obligations or exercise of Ampio’s
rights under this Agreement,

 

(d) any product liability claim related to Tramadol
or Products manufactured, used or sold by any of Ampio or its Affiliates or Ampio Licensees or any of their respective successors,
assigns, heirs or representatives. prior to the Effective Date or during the term of this Agreement or after termination or expiration
of this Agreement, and any product liability claim related to Tramadol or Products arising from manufacturing Tramadol or Products
supplied to Daewoong hereunder, including (i) non conformance of Tramadol or Products to Tramadol specifications and (ii) non manufacture
of Tramadol or Products according to cGMP, or

 

(e) any claim of infringement or misappropriation
of a Third Party’s patent, copyright, trade secret or trademark right, or any other intellectual property right arising from
the development, registration, manufacture, marketing, promotion, distribution, importation, offer for sale or sale or other commercialization
of Tramadol or Products, or chemical agents for making or using the same, by any of Ampio or its Affiliates or Ampio Licensees
or any of their respective successors, assigns, heirs or representatives.

 

However, Ampio shall not be required to indemnify
any Daewoong Indemnitee to the extent that any such claims or suits arose out of or resulted from the negligence, recklessness
or willful misconduct or fraud of any Daewoong Indemnitees.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 37	 

     

    

 

20.2 Daewoong shall defend, indemnify and hold
harmless Ampio or any of its Affiliates, or Ampio Licensees or any of their respective officers, directors, employees, agents,
distributors and suppliers, or any of their respective successors, assigns, heirs or representatives (collectively, “Ampio
Indemnitees”) from and against all Losses to the extent the same is arising from:

 

(a) Daewoong’s material breach of any term
of this Agreement (including any express representation or warranty made herein),

 

(b) the negligence, recklessness or willful
misconduct or fraud on the part of any Daewoong Indemnitee with respect to the Product produced by Daewoong or in the performance
of Daewoong’s obligations or exercise of Daewoong’s rights under this Agreement,

 

(c) any actual or alleged violation of Law
(other than any patent or other intellectual property Laws) in the performance of Daewoong’s obligations or exercise of Daewoong’s
rights under this Agreement,

 

(d) any product liability claim related to Tramadol
or Product manufactured, used or sold by any Daewoong or its Affiliates or Sublicensees or any of their respective successors,
assigns, heirs or representatives during the term of this Agreement or after termination or expiration of this Agreement, unless
and to the extent such claim arose out of or resulted from (i) non conformance of Tramadol or Products supplied by Ampio to Tramadol
specifications or (ii) non manufacture of Tramadol or Products supplied by Ampio or any of its Affiliates according to cGMP, or

 

(e) use of any data from
any clinical studies conducted by or on behalf of Ampio or Ampio Licensees;

 

(f) any claim of infringement or misappropriation
of a Third Party’s patent, copyright, trade secret or trademark right, or any other intellectual property right arising from
the development, registration, manufacture, marketing, promotion, distribution, importation, offer for sale or sale or other commercialization
of Tramadol or Product, or chemical agents for making or using the same, by any of Daewoong or its Affiliates or Sublicensees or
any of their respective successors, assigns, heirs or representatives.

 

However, Daewoong shall not be required to indemnify
any Ampio Indemnitee to the extent that any such claims or suits arose out of or resulted from the negligence, recklessness or
willful misconduct or fraud of any Ampio Indemnitee.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 38	 

     

    

 

20.3 Indemnification Procedures.
A Party which intends to claim indemnification under Section 20.1 or 20.2 (the ”Indemnitee”) will promptly notify
the other Party (the “Indemnitor”) in writing of any claim, suit, proceeding or action in respect of which the
Indemnitee or any of the other Ampio Indemnitees or Daewoong Indemnitees, as applicable, intend to claim such indemnification
within a reasonable period of time after the assertion of such claim; provided, however, that the failure to provide written
notice of such claim within a reasonable period of time will not relieve the Indemnitor of any of its obligations hereunder,
except to the extent that the Indemnitor is prejudiced by such failure to provide prompt notice. The Indemnitor will have the
right to assume the complete control of the defence, compromise or settlement of any such claim (provided that no settlement
of any claim will include any admission of wrongdoing on the part of an Indemnitee or the other Ampio Indemnitees or Daewoong
Indemnitees, as applicable, or materially and adversely effect the rights of the Indemnitee or the other Ampio Indemnitees or
Daewoong Indemnitees, as applicable, in each case without the prior written consent of such Indemnitee, which such consent
will not be unreasonably withheld or delayed). The Indemnitor may, at its own expense, employ legal counsel to defend the
claim at issue. The Indemnitee may, in its sole discretion and at its own expense, employ legal counsel to represent it and
the other Ampio Indemnitees or Daewoong Indemnitees, as applicable (in addition to the legal counsel employed by the
Indemnitor) in any such matter, and in such event legal counsel selected by the Indemnitee will be required to confer and
cooperate with such counsel of the Indemnitor in such defence, compromise or settlement for the purpose of informing and
sharing information with the Indemnitor. The Indemnitee will, at its own expense, make available to Indemnitor those Ampio
Indemnitees or Daewoong Indemnitees, as applicable, whose assistance, testimony or presence is necessary, useful or
appropriate to assist the Indemnitor in evaluating, defending or settling any such claim; provided, however, that any such
access will be conducted in such a manner as not to interfere unreasonably with the operations of the businesses of
Indemnitee or the other Ampio Indemnitees or Daewoong Indemnitees, as applicable; and will otherwise fully cooperate with the
Indemnitor and its legal counsel in the investigation and defence of such claim.

 

20.4 Insurance. Both
Parties will procure and maintain adequate insurance in order to be able to cover claims under this Agreement. Upon request, each
Party shall provide proof of adequate coverage to the other Party.

 

21 Non-assignability

 

This Agreement is personal to the Parties hereto
and shall not be assignable to any Third Party by either Party without the prior written consent of the other Party, which shall
not be unreasonably withheld or delayed; provided, however, that any Party may assign this Agreement in full to an
Affiliate of such Party without prior written consent, but with prior written notice, and provided, further, that
any Party may assign this Agreement to any entity with which such Party may merge or consolidate (or engage in some other form
of corporate combination), or to which it may transfer all or substantially all of its assets to which this Agreement relates.
All successors and permitted assignees of a Party shall be subject to, and will be bound by, all the terms and conditions of this
Agreement. Any attempted assignment made contrary to the provisions hereof will be void. This Agreement shall inure to the benefit
of and be binding on the Parties’ successors, permitted assigns and legal representatives.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 39	 

     

    

 

22 Language

 

22.1 This text of this Agreement in the English
language shall be the original text, and any text in another language, even if such a text is made by translation of the text in
English language or prepared by any of the Parties hereto for the purpose of its own convenience, shall have no meaning for any
purpose between the Parties hereto.

 

22.2 Any information to be provided under this
Agreement, including any Know-How, shall be provided in the English language. The words “include”, “includes”
and “including” shall be deemed to be followed by the phrase “without limitation”. The words ”herein”,
“hereof” and “hereunder”, and words of similar import, shall be construed to refer to this Agreement in
its entirety and not to any particular provision hereof.

 

23 Entire Agreement

 

This Agreement
(together with the Exhibits attached hereto and the Development Plan) shall constitute the entire agreement between the Parties
hereto concerning the subject matter hereof and shall supersede any other agreements, whether oral or written, express or implied,
with respect to the subject matter hereof.

 

24 Separability

 

24.1 In the event any portion of this Agreement
shall be held illegal, void or ineffective, the remaining portions hereof shall remain in full force and effect.

 

24.2 If any of the terms or provisions of this
Agreement are in conflict with any applicable Law, then such terms or provisions shall be deemed inoperative to the extent that
they may conflict therewith and shall be deemed to be modified to conform with such Law. The Parties shall make a good faith effort
to replace any invalid or unenforceable term or provision with a valid and enforceable one such that the objectives contemplated
by the Parties when entering this Agreement may be realized.

 

25 Independent Contractors;
No Partnership

 

The Parties hereto are independent contractors.
In making and performing this Agreement, the Parties are acting, and intend to be treated, as independent entities performing a
contract, and nothing contained in this Agreement is to be construed or implied or deemed to create an agency, partnership, joint
venture or an employee/employer relationship between Daewoong and Ampio. This Agreement is not, and will not be deemed to be, a
partnership agreement or joint venture agreement, expressly or by implication. Employees of each Party remain employees of said
Party and will be considered at no time agents of or owing a fiduciary duty to the other Party. Neither Party will have any implied
right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party
to any other contract, agreement or undertaking with any Third Party.

 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 40	 

     

    

 

26 Amendment and Waiver

 

The Parties hereto may amend, modify or alter
any of the provisions of this Agreement, but such amendment, modification or alteration will be valid and binding on either Party
only if memorized by a written instrument that explicitly refers to this Agreement and is duly executed by both Parties hereto.
The failure of any Party to insist on the performance of any obligation hereunder shall not be deemed to be a waiver of such obligation.
Waiver of any nonaction of any provision hereof shall not be deemed to be a waiver of any other rights or remedies of such provision
or any other provision on such occasion or any succeeding occasion.

 

27 Counterparts

 

This Agreement may be executed by the Parties
in one or more identical counterparts, all of which together will constitute this Agreement. If this Agreement is executed in counterparts,
no signatory hereto will be bound until both Parties have duly executed a counterpart of this Agreement. Facsimile execution and
delivery of this Agreement by the Parties shall be legal, valid and binding execution and delivery of this Agreement for all purposes.

 

[remainder of this
page intentionally left blank]

 

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 41	 

     

    

 

IN WITNESS WHEREOF, the
Parties hereto have caused this Agreement to be executed in duplicate counterparts by their duly authorized representatives, each
fully executed copy hereof to be deemed as original, as of the Effective Date.

 

	Ampio Pharmaceuticals, Inc.	 
	 	 	 
	By:	/s/ DB Wingerter	 
	 	Name:	 
	 	Title: CEO	 
	 	 	 
	Daewoong Pharmaceuticals Co., Ltd	 
	 	 	 
	By:	/s/ Jong Wook Lee	 
	 	Name: Jong Wook Lee	 
	 	Title: President & CEO	 

  

    License, Development and Commercialization Agreement between Ampio and Daewoong
	 	Page 42	 

     

    

 

EXHIBIT 1.5

 

AMPIO
PATENTS

 

To be provided within 15 days after the Effective Date.

  

    License, Development and Commercialization Agreement between Ampio and Daewoong

     

    

 

EXHIBIT 1.18

 

DAEWOONG
PATENTS

 

To be provided within 15 days after the Effective
Date. 

 

    License, Development and Commercialization Agreement between Ampio and Daewoong

     

    

 

EXHIBIT
3.1

 

AMPIO KNOW-HOW
AND AMPIO REGULATORY DOCUMENTATION

 

Within sixty (60) days
after the Effective Date of this Agreement, Ampio shall disclose or make available to Daewoong copies of all of the Ampio Know-How
and Ampio Regulatory Documentation, including the following Ampio Know-How and Ampio Regulatory Documentation:

 

1. Trial Master File
(“TMF”) for “A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and
Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets In Male Subjects with Premature Ejaculation”
(“Study”), Sponsors Protocol codes: BVF-324.301 and BVF-324.302, as received by Ampio from Kendle International, including:

 

Protocol Summaries and Synopses

Protocol Amendments

ICF/SIS - Study Templates

Q-A Logs

QC Documentation

Case Report Forms and Amendments

eCRF Completion
Guidelines

Recruitment Materials

Source Document Templates

Investigator Brochure

Certificates of Analysis

Correspondence

Clinical Study Reports

Audit Certificates

Regulatory Authority Documents

Translations, translation certificates &
checklists

Country Documentation

Central Ethics Committee Documentation

Final
Statistical Analysis Plan

Investigational Medicinal Product Dossier

Bioequivalence Study

 

Alcohol Interference Study

 

2. SAS datasets with
safety and efficacy data for “A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy
and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets In Male Subjects with Premature Ejaculation”
(“Study”), Sponsors Protocol Codes: BVF-324.301 and BVF-324.302, as received by Ampio from Kendle International.

 

 

    License, Development and Commercialization Agreement between Ampio and DaewoongExhibit 10.11

 

VOTING AGREEMENT

 

THIS VOTING AGREEMENT
(this “Agreement”), dated as of April 21, 2015, is made between Rosewind Corporation, a Colorado corporation
(the “Company”), and Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Shareholder”).

 

Recitals

 

WHEREAS, the
Shareholder is the beneficial owner (as defined in Rule l3d-3 under the Securities Exchange Act of 1934, as amended) of 141,535,750
outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company,
which shares entitle the beneficial owner to vote at a meeting of the shareholders of the Company or by written consent;

 

WHEREAS, each
of the Shareholder and the Company will derive significant value from the consummation of the Proposed Transactions (as defined
below); and

 

WHEREAS, in
consideration of the foregoing, and for other good and valuable consideration, receipt of which is hereby acknowledged, the Shareholder
agrees to vote all of the shares of the Common Stock beneficially owned by the Shareholder at one or more Company shareholder meetings
or by written consent in favor of proposals approved by the Board of Directors of the Company (the “Board”) and authorizing
the Company to (1) re-incorporate into the State of Delaware through a plan of conversion; (2) effectuate a reverse stock split
of the Company’s common stock, at a ratio of one new share for every approximately 12.174 shares currently outstanding; (3)
change the name of the Company from “Rosewind Corporation” to “Aytu Bioscience, Inc.”; and (4) approve
a new stock option and incentive plan (collectively, the “Proposed Transactions”).

 

NOW, THEREFORE,
in consideration of the foregoing and the mutual promises, representations, warranties, covenants and agreements contained herein,
the parties hereto, intending to be legally bound, hereby agree as follows:

 

		1.	Voting Provisions

 

(a) Agreement
to Vote Shares of the Company’s Stock. The Shareholder hereby agrees during the Term (as defined in Section 3
below) of this Agreement to vote or cause to be voted all shares of Company’s Common Stock owned of record and/or beneficially
(as defined in Rule 13d-3 of the Exchange Act of 1934, as amended) by the Shareholder (the “Shares”),
in each case, as of the applicable record date for any annual or special meeting of shareholders or in connection with any solicitation
of shareholder action by written consent (each, a “Shareholders Meeting”), in favor of each of the Proposed
Transactions and to be present for quorum purposes.

 

(b) 
No Other Voting Agreement. The Shareholder hereby agrees that the Shareholder shall not enter into any agreement or understanding
with any other person the effect of which would be to violate the provisions and agreements contained in this Section 1,
provided that the foregoing shall not restrict the Shareholder from selling or otherwise disposing of the Shareholder’s Shares.

 

     

     

    

 

		2.	Other Proxies Revoked. The Shareholder represents and warrants that any proxies heretofore
given in respect of the Shareholder’s Shares are not irrevocable, and that all such proxies have been or are hereby revoked.

 

		3.	Term of Agreement. The term of this Agreement shall commence on the date of this
Agreement and shall remain in full force and effect until the approval by the Company’s stockholders of the Proposed Transactions
(the “Term”). For avoidance of doubt, upon the termination of this Agreement, the parties will have no
continuing obligations pursuant to this Agreement.

 

		4.	Representations and Warranties of the Shareholder. The Shareholder hereby represents
and warrants to the Company as follows:

 

(a) Authority,
etc. The Shareholder has all necessary power and authority to execute and deliver this Agreement and to consummate the transactions
contemplated hereby. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby
by the Shareholder have been duly authorized by all necessary action on the part of the Shareholder and constitutes a legal, valid
and binding obligation of the Shareholder, enforceable against the Shareholder in accordance with its terms.

 

(b) Ownership
of Shares. The Shareholder is, as of the date hereof, the beneficial owner of 141,535,750 shares of Common Stock. The Shareholder
has sole voting power and sole power to issue instructions with respect to the matters set forth in Section 1 hereof, sole
power of disposition, sole power of conversion, sole power to agree to all of the matters set forth in this Agreement, in each
case with respect to all of the Shares, with no limitations, qualifications or restrictions on such rights, subject only to applicable
securities laws and the terms of this Agreement.

 

(c) No
Conflicts. No filing with, and no permit, authorization, consent or approval of, any governmental entity is necessary for the
execution of this Agreement by the Shareholder and the consummation by the Shareholder of the transactions contemplated hereby.
None of the execution and delivery of this Agreement by the Shareholder, the consummation by the Shareholder of the transactions
contemplated hereby or compliance by the Shareholder with any of the provisions hereof shall (A) conflict with or result in any
breach of any applicable documents to which the Shareholder is a party, or (B) violate any order, writ, injunction, decree,
judgment, order, statute, rule or regulation applicable to the Shareholder.

 

(d) No
Encumbrances. The Shares and the certificates representing such Shares are now held by the Shareholder, or by a nominee or
custodian for the benefit of the Shareholder, free and clear of all liens, claims, security interests, proxies, voting trusts or
agreements, understandings or arrangements or any other encumbrances whatsoever, except for any such encumbrances or proxies arising
hereunder.

 

		5.	Covenants of The Shareholder. The Shareholder covenants and agrees that, during the
Term, the Shareholder shall not (i) grant any proxies or powers of attorney, deposit any of the Shares into a voting trust or enter
into a voting agreement with respect to any of the Shares or (ii) take any action that would make any representation or warranty
of the Shareholder contained herein untrue or incorrect or have the effect of preventing, disabling or delaying the Shareholder
from performing the Shareholder’s obligations under this Agreement.

 

    2

     

    

 

		6.	Covenants of the Company.

 

The Company covenants and
agrees that it shall hold a Shareholders Meeting as soon as is reasonably practicable for the purpose of voting upon the Proposed
Transactions, unless the Board determines after the date of this Agreement that it is no longer advisable for the Company to do
so.

 

		7.	(a) Miscellaneous

 

(a) Further
Assurances. From time to time, at any other party’s written request and without further consideration, each party
hereto shall execute and deliver such additional documents and take all such further lawful action as may be necessary or
desirable to consummate and make effective, in the most expeditious manner practicable, the transactions contemplated by this
Agreement.

 

(b) Entire
Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and
supersedes all other prior agreements and understandings, both written and oral, between the parties with respect to the subject
matter hereof.

 

(c) Assignment.
This Agreement shall not be assigned by operation of law or otherwise without the prior written consent of the other party, provided
that the Buyers may assign and transfer, at its sole discretion, its rights and obligations hereunder to any of their affiliates.

 

(d) Amendments,
Waivers, Etc. This Agreement may not be amended, changed, supplemented, waived or otherwise modified or terminated, except
upon the execution and delivery of a written agreement executed by all of the relevant parties hereto.

 

(e) Notices.
All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given (and shall be
deemed to have been duly received if so given) by hand delivery, fax, or by mail (registered or certified mail, postage prepaid,
return receipt requested) or by any courier service, such as FedEx, providing proof of delivery. All communications hereunder shall
be delivered to the respective parties at the following addresses:

 

If to the Shareholder:

 

Ampio Pharmaceuticals, Inc.

373 Inverness Parkway, Suite 200

Englewood, Colorado 80112

Attention: Gregory A. Gould

Facsimile: (720) 437-6501

 

    3

     

    

 

If to the Company:

 

Rosewind Corporation

373 Inverness Parkway, Suite 200

Englewood, Colorado 80112

Attention: Joshua R. Disbrow

Facsimile: (720) 437-6501

 

With a copy to:

 

Goodwin Procter LLP

620 Eighth Avenue

New York, New York 10018

Attention: Andrew H. Goodman, Esq.

Facsimile: (212) 355-3333

 

or to such other address as the person
to whom notice is given may have previously furnished to the others in writing in the manner set forth above.

 

(f) Severability.
Whenever possible, each provision or portion of any provision of this Agreement will be interpreted in such manner as to be effective
and valid under applicable law but if any provision or portion of any provision of this Agreement is held to be invalid, illegal
or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability
will not affect any other provision or portion of any provision in such jurisdiction, and this Agreement will be reformed, construed
and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never
been contained herein.

 

(g) Specific
Performance. Each of the parties hereto recognizes and acknowledges that a breach by it of any covenants or agreements contained
in this Agreement will cause the other party to sustain damages for which it would not have an adequate remedy at law for money
damages, and therefore each of the parties hereto agrees that in the event of any such breach the aggrieved party shall be entitled
to the remedy of specific performance of such covenants and agreements and injunctive and other equitable relief in addition to
any other remedy to which it may be entitled, at law or in equity.

 

(h) Remedies
Cumulative. All rights, powers and remedies provided under this Agreement or otherwise available in respect hereof at law or
in equity shall be cumulative and not alternative, and the exercise of any thereof by any party shall not preclude the simultaneous
or later exercise of any other such right, power or remedy by such party.

 

(i) No
Waiver. The failure of any party hereto to exercise any right, power or remedy provided under this Agreement or otherwise available
in respect hereof at law or in equity, or to insist upon compliance by any other party hereto with its obligations hereunder, and
any custom or practice of the parties at variance with the terms hereof shall not constitute a waiver by such party of its right
to exercise any such or other right, power or remedy or to demand such compliance.

 

    4

     

    

 

(j) No
Third Party Beneficiaries. This Agreement is not intended to be for the benefit of, and shall not be enforceable by, any person
who or which is not a party hereto.

 

(k) Governing
Law. This Agreement, and the legal relations between the parties hereto, shall be governed and construed in accordance with
the laws of the State of Delaware.

 

(l) Waiver
of Jury Trial. EACH OF THE PARTIES HEREBY KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVES ANY RIGHTS THEY MAY HAVE TO A TRIAL
BY JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS AGREEMENT OR ANY OTHER
DOCUMENTS ENTERED INTO IN CONNECTION HEREWITH, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN),
OF ANY PARTY.

 

(m) Descriptive
Headings. The descriptive headings used herein are inserted for convenience of reference only and are not intended to be part
of or to affect the meaning or interpretation of this Agreement.

 

(n) Counterparts.
This Agreement may be executed in two or more counterparts, and by the different parties hereto in separate counterparts, each
of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.
Delivery of an executed counterpart of a signature page to this Agreement by facsimile shall be effective as delivery of a manually
executed counterpart of this Agreement.

 

* * * * *

 

    5

     

    

 

IN WITNESS WHEREOF,
each of the Company and the Shareholder has caused this Voting Agreement to be duly executed as of the day and year first above
written.

 

	ROSEWIND CORPORATION	 
	 	 
	By:	              	 
	Name:	Joshua R. Disbrow	 
	Title:	President and Chief Executive Officer	 
	 	 	 
	AMPIO PHARMACEUTICALS, INC.	 
	 	 	 
	By:	            	 
	Name:	Gregory A. Gould	 
	Title:	Chief Financial Officer	 

 

[Signature
Page to Voting Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]